Clinical Management of Paradoxical Psoriasiform Reactions During TNF-α Therapy

array:24 ["pii" => "S1578219014002133" "issn" => "15782190" "doi" => "10.1016/j.adengl.2013.05.011" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "866" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105:752-61" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2773 "formatos" => array:3 [ "EPUB" => 42 "HTML" => 1353 "PDF" => 1378 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731013002548" "issn" => "00017310" "doi" => "10.1016/j.ad.2013.05.007" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "866" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105:752-61" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3681 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 2141 "PDF" => 1538 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "Dermatología Práctica" "titulo" => "Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo clínico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "752" "paginaFinal" => "761" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Clinical Management of Paradoxical Psoriasiform Reactions During TNF- α Therapy" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 773 "Ancho" => 1559 "Tamanyo" => 87735 ] ] "descripcion" => array:1 [ "es" => "Clasificación de las reacciones psoriasiformes paradójicas." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Navarro, E. Daudén" "autores" => array:2 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Navarro" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Daudén" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219014002133" "doi" => "10.1016/j.adengl.2013.05.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014002133?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731013002548?idApp=UINPBA000044" "url" => "/00017310/0000010500000008/v1_201409260036/S0001731013002548/v1_201409260036/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219014002030" "issn" => "15782190" "doi" => "10.1016/j.adengl.2013.09.009" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "904" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2014;105:762-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1895 "formatos" => array:3 [ "EPUB" => 37 "HTML" => 1242 "PDF" => 616 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "History and Humanities in Dermatology" "titulo" => "Syphilis and Human Experimentation From the First Appearance of the Disease to World War II: A Historical Perspective and Reflections on Ethics" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "762" "paginaFinal" => "767" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Experimentación en sífilis hasta la Segunda Guerra Mundial: historia y reflexiones éticas" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 723 "Ancho" => 950 "Tamanyo" => 115662 ] ] "descripcion" => array:1 [ "en" => "Manchuria, China: Unit 731 physicians performing routine work. Source of photograph: British Broadcasting Corporation." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Cuerda-Galindo, X. Sierra-Valentí, E. González-López, F. López-Muñoz" "autores" => array:4 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Cuerda-Galindo" ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Sierra-Valentí" ] 2 => array:2 [ "nombre" => "E." "apellidos" => "González-López" ] 3 => array:2 [ "nombre" => "F." "apellidos" => "López-Muñoz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173101300358X" "doi" => "10.1016/j.ad.2013.09.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101300358X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014002030?idApp=UINPBA000044" "url" => "/15782190/0000010500000008/v1_201409260034/S1578219014002030/v1_201409260034/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219014002157" "issn" => "15782190" "doi" => "10.1016/j.adengl.2013.09.010" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "911" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 0 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2014;105:744-51" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1398 "formatos" => array:3 [ "EPUB" => 35 "HTML" => 823 "PDF" => 540 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Review" "titulo" => "Vismodegib: A Review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "744" "paginaFinal" => "751" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vismodegib: revisión" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1331 "Ancho" => 2504 "Tamanyo" => 231622 ] ] "descripcion" => array:1 [ "en" => "Activation of the Hedgehog (Hh) pathway." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "V. Ruiz-Salas, M. Alegre, A. López-Ferrer, J.R. Garcés" "autores" => array:4 [ 0 => array:2 [ "nombre" => "V." "apellidos" => "Ruiz-Salas" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Alegre" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "López-Ferrer" ] 3 => array:2 [ "nombre" => "J.R." "apellidos" => "Garcés" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731013003712" "doi" => "10.1016/j.ad.2013.09.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731013003712?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014002157?idApp=UINPBA000044" "url" => "/15782190/0000010500000008/v1_201409260034/S1578219014002157/v1_201409260034/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "Practical Dermatology" "titulo" => "Clinical Management of Paradoxical Psoriasiform Reactions During TNF-α Therapy" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "752" "paginaFinal" => "761" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "R. Navarro, E. Daudén" "autores" => array:2 [ 0 => array:4 [ "nombre" => "R." "apellidos" => "Navarro" "email" => array:1 [ 0 => "nat_eraa@hotmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Daudén" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Departamento de Dermatología, Hospital Universitario La Princesa, Madrid, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo clínico" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 773 "Ancho" => 1559 "Tamanyo" => 88031 ] ] "descripcion" => array:1 [ "en" => "Classification of paradoxical psoriasiform reactions." ] ] ] "textoCompleto" => "IntroductionPsoriasis, a chronic inflammatory disease of unknown etiology, affects approximately 2% to 3% of the population worldwide.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> It has been speculated that it could be the result of a combination of genetic and environmental factors; a genetic predisposition does exist, but it has not been possible to establish a classic Mendelian pattern of inheritance.Numerous factors that trigger the onset of psoriasis or aggravate established psoriasis have been described, including infections, stress, and drugs (β-blockers, lithium, …).<a class="elsevierStyleCrossRefs" href="#bib0005">1,2</a>Several hypotheses and models have been proposed to try to explain the pathogenesis of psoriasis; these have led us to look not only at the skin, but also at the multiple associated comorbid conditions, such as psoriatic arthritis and cardiovascular disease.<a class="elsevierStyleCrossRefs" href="#bib0015">3,4</a> A unifying hypothesis is the model of the cytokine network, which states that both external stimuli, such as stress, and endogenous ones, such as viruses, neuropeptides, or drug ingestion, can act as triggers that activate a cytokine cascade. These cytokines include tumor necrosis factor (TNF) α, derived from antigen-presenting dendritic cells and keratinocytes, and interferon (IFN) γ produced by activated type 1 helper T cells.<a class="elsevierStyleCrossRef" href="#bib0005">1</a>Around 90% of individuals with psoriasis have the most common form, the so-called plaque psoriasis or psoriasis vulgaris. In the majority of cases, the disease is mild and can be controlled with topical therapy. However, up to a third of patients develop moderate or severe psoriasis and require systemic therapy, such as phototherapy, acitretin, methotrexate, or ciclosporin.<a class="elsevierStyleCrossRef" href="#bib0025">5</a> The toxicity of these drugs and the frequent lack of response to them has led to the appearance over the past 15 years of the so-called biologic therapies, which act at different levels of the inflammatory cascade that gives rise to the plaques of psoriasis.The use of biologic therapy is increasing worldwide for the treatment not only of psoriasis, but also of other chronic immune-mediated inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease. At the present time, the most widely employed drugs are those that inhibit TNF-α (infliximab, etanercept, and adalimumab), though a number of side effects have been reported during their use, including infections, reactivation of latent tuberculosis, demyelinating diseases, and congestive heart failure.<a class="elsevierStyleCrossRefs" href="#bib0030">6–8</a>It has been reported that the cutaneous side effects of anti-TNF-α therapy are more prevalent than was previously thought.<a class="elsevierStyleCrossRef" href="#bib0045">9</a> These effects include reactions at the site of infusion or injection, skin infections, eczema, and even psoriasis or psoriasiform reactions.<a class="elsevierStyleCrossRef" href="#bib0050">10</a> Though paradoxical (as these drugs are of demonstrated efficacy in the treatment of psoriasis<a class="elsevierStyleCrossRefs" href="#bib0055">11–17</a>), case reports and some case series describe patients with exacerbations of their psoriasis or even the new onset of distinct subtypes of psoriasis during anti-TNF-α therapy.<a class="elsevierStyleCrossRefs" href="#bib0045">9,10,18–73</a> The most relevant articles and reviews are summarized in <a class="elsevierStyleCrossRefs" href="#tbl0005">Tables 1 and 2</a>.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia>Moustou et al.<a class="elsevierStyleCrossRef" href="#bib0050">10</a> published a literature review in which they established the strength of the association between published side effects and the use of 1 or more anti-TNF-α agents, classifying the association as poor, moderate, strong, or definitive. The authors used descriptions of the side effects in meta-analyses, randomized trials, retrospective or prospective studies, case series, and case reports. They analyzed the number of anti-TNF-α agents implicated, the number of distinct inflammatory diseases in which the side effect had occurred during treatment with anti-TNF-α drugs, and the clinical course after withdrawal and reintroduction of the drug. The authors not only described the clinical manifestations of these cutaneous reactions, but they also established that there was a strong relationship between anti-TNF-α therapy and new onset psoriasis or psoriasiform reactions.ClassificationDistinct patterns of paradoxical psoriasiform reactions can be distinguished during treatment with TNF-α-inhibitors (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>):<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">-The induction of new onset psoriasis, which is the appearance of psoriasis lesions in patients who have not previously been diagnosed with this disease and who are receiving anti-TNF-α treatment for another inflammatory disease.</li><li class="elsevierStyleListItem" id="lsti0010">-An exacerbation of pre-existing psoriasis, with or without morphologic differences, during anti-TNF-α therapy.</li></ul><elsevierMultimedia ident="fig0005"></elsevierMultimedia>Pathogenesis of Psoriasiform ReactionsThe pathophysiology of the induction or exacerbation of psoriasis during treatment with TNF-α inhibitors is still unknown. A number of theories have been proposed, such as a disruption of the balance between TNF-α and IFN-α, activation of self-reactive T lymphocytes, wrong diagnosis, natural course of the primary disease, or infections that trigger such reactions.<a class="elsevierStyleCrossRefs" href="#bib0045">9,10,25,37</a> In their article on the pathogenesis of psoriasiform reactions, Collamer et al.<a class="elsevierStyleCrossRef" href="#bib0125">25</a> explained that a disruption of cytokine balance could lead to increased IFN-α production by dendritic cells in genetically predisposed individuals, and that genetic polymorphisms could play a role in this paradoxical reaction secondary to TNF-α blockade.De Gannes et al.,<a class="elsevierStyleCrossRef" href="#bib0260">52</a> in an article published in 2007, demonstrated that patients who developed new onset psoriasis during treatment with anti-TNF-α agents presented elevated expression of antimyxovirus-resistance protein A (MxA), an adenosine triphosphatase that is selectively induced in response to type 1 IFN and could be used as a surrogate marker of lesional type 1 IFN activity. In that study, staining for MxA in biopsies from patients receiving treatment with anti-TNF was more intense than in the biopsies from patients with psoriasis vulgaris not associated with anti-TNF-α therapy. Such an increase would favor the formation of psoriasis lesions in predisposed individuals. Subsequently, Seneschal et al.<a class="elsevierStyleCrossRef" href="#bib0240">48</a> described 13 patients who developed distinct subtypes of psoriasis; biopsies from those patients revealed increased production of MxA protein compared with biopsies from healthy skin or from noninduced psoriasis lesions. Those authors concluded that increased IFN-α levels associated with cytokine imbalance (both situations caused by TNF-α inhibition) could play an important role in the appearance of this type of reaction, which they considered to be a drug reaction rather than true psoriasis.However, another study found no differences between induced and noninduced psoriasis on immunohistochemical analysis with staining for the mRNA of IFN and TNF-α and for vascular endothelial growth factor.<a class="elsevierStyleCrossRef" href="#bib0265">53</a>Some authors believe that there must be a genetic predisposition, as the majority of patients receiving anti-TNF-α therapy for a wide range of diseases do not develop psoriasis. Some environmental factor may also be exerting an effect, as the latency between the initiation of treatment and the appearance of psoriasis is very variable (from days to years).<a class="elsevierStyleCrossRefs" href="#bib0125">25,27,37</a>This wide variability makes it difficult to establish a causal relationship in some cases. It is therefore important to exclude any other factor that could trigger the appearance of psoriasis, such as infection, trauma, stress, or new drugs.<a class="elsevierStyleCrossRef" href="#bib0220">44</a>According to some authors, paradoxical psoriasiform reactions are the result of a class effect, as cases have been reported with all 3 classic TNF-α inhibitors (infliximab, etanercept, and adalimumab), in frequencies proportional to the prevalence of their use.<a class="elsevierStyleCrossRef" href="#bib0185">37</a> More recently, the phenomenon has been described in patients treated with certolizumab, a newer anti-TNF-α agent. In the literature, we have found a review article describing 6 cases related to this drug in patients with inflammatory bowel disease, in addition to another case from our own records.<a class="elsevierStyleCrossRef" href="#bib0135">27</a> Recurrence after the administration of a distinct anti-TNF-α drug supports the class effect theory.<a class="elsevierStyleCrossRefs" href="#bib0125">25,27,33,36,37,55</a>Reports have also been published of cases of new onset psoriasis or exacerbations during treatment with psoriasis drugs other than the TNF-α inhibitors, including drugs such as efalizumab, ciclosporin, and anthralin, as well as after phototherapy or glucocorticoid withdrawal.<a class="elsevierStyleCrossRef" href="#bib0275">55</a> Furthermore, other biologic agents have been implicated, such as abatacept in a patient who developed guttate psoriasis during treatment with etanercept and, 2 years later, a further episode with the same morphology during treatment with abatacept.<a class="elsevierStyleCrossRef" href="#bib0350">70</a> For Rallis et al.<a class="elsevierStyleCrossRef" href="#bib0220">44</a> this suggests a gap in our understanding of the pathophysiology of psoriasis and of the exact mechanism by which some of these drugs act.<a class="elsevierStyleCrossRef" href="#bib0220">44</a>New Onset PsoriasisThe large majority of published cases refer to new onset psoriasis, particularly in patients with rheumatologic diseases. Based on published studies, it has been established that the prevalence of psoriasis during anti-TNF-α therapy is between 0.6% and 5.3%, depending on differences between the populations studied and treated.<a class="elsevierStyleCrossRefs" href="#bib0135">27,54</a> In a recent article on psoriasis induced during treatment with anti-TNF-α drugs for inflammatory bowel disease, the reported prevalence was 1.62%.<a class="elsevierStyleCrossRef" href="#bib0165">33</a>Data coming from the larger series and from literature reviews are not particularly homogeneous. This, and the fact that not all cases will have been published, could lead to biased conclusions. In a recent review article that included 207 cases (after excluding patients with any known trigger), it was reported that 85% of patients had developed new onset psoriasis.<a class="elsevierStyleCrossRef" href="#bib0125">25</a>There is a female predominance (2 women to 1 man), due to cases associated with rheumatoid arthritis and inflammatory bowel disease.<a class="elsevierStyleCrossRefs" href="#bib0125">25,37</a> Series of patients with rheumatoid arthritis show the greatest difference, up to 5.3 women to 1 man.<a class="elsevierStyleCrossRef" href="#bib0270">54</a> When all cases are included, the mean age at onset is 44.9 years (range, 13-78 years)<a class="elsevierStyleCrossRef" href="#bib0125">25</a>; however, the mean age among patients with gastrointestinal disease is lower (30 years).<a class="elsevierStyleCrossRef" href="#bib0135">27</a>Looking at all cases that were fully reviewed, the drug most commonly implicated was infliximab, accounting for 55.1% to 59% cases.<a class="elsevierStyleCrossRefs" href="#bib0125">25,37</a> In their review of the literature, Ko et al.<a class="elsevierStyleCrossRef" href="#bib0185">37</a> identified 127 cases reported up to September 2007. Those authors stated that the second most common drug was etanercept (27.6%) and, finally, adalimumab (17.3%). However, in a more recent series by Collamer et al.,<a class="elsevierStyleCrossRef" href="#bib0125">25</a> 22% of all cases were on treatment with adalimumab and 17% with etanercept.Cullen et al.<a class="elsevierStyleCrossRef" href="#bib0135">27</a> performed a review of 120 cases, including 30 cases of their own, with the additional inclusion criterion of a history of inflammatory bowel disease. Their results indicated that 79% had received infliximab, 17% adalimumab, and 4% the new drug, certolizumab; it must be taken into account that etanercept is not approved for use in inflammatory bowel disease.Those percentages were proportional to the use of each one of the drugs. In contrast, in a series of patients from the British Society for Rheumatology Biologics Register, with a description of 25 cases of new onset psoriasis in a cohort of 9826 patients with AR, 13 were on treatment with adalimumab.<a class="elsevierStyleCrossRef" href="#bib0270">54</a> That group of 25 patients was compared with another group formed of patients receiving treatment with disease-modifying antirheumatic drugs; none of the patients in the latter group developed psoriasis after a follow-up of 2.81 years.The latency is very variable, from days to 80 months, with a mean of 10.5 months. In the review by Ko et al.,<a class="elsevierStyleCrossRef" href="#bib0185">37</a> the latency was shorter in patients treated with etanercept, although 42.9% were exacerbations of previously known psoriasis rather than new onset psoriasis. Other authors, such as Chen et al.,<a class="elsevierStyleCrossRef" href="#bib0120">24</a> who published a review of cases arising with etanercept, have also reported a shorter latency with this drug. In the 25 patients included in the review by those authors, the mean latency was 3.5 months after the initiation of treatment.More than half of published cases have occurred in patients with rheumatologic diseases, particularly rheumatoid arthritis, which accounts for 42.5% to 50.4% of cases, depending on the study.<a class="elsevierStyleCrossRefs" href="#bib0125">25,37</a>Overall, the cases reported have been of any type of psoriasis and at any site: vulgaris, guttatate, inverse, or generalized or palmoplantar pustulosis (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>); the latter subtype was the most common form in the larger series and reviews.<a class="elsevierStyleCrossRefs" href="#bib0045">9,25,37</a> Adalimumab has been reported to be the drug most frequently implicated in palmoplantar pustulosis, and more than half of the paradoxical reactions described with this drug are of this subtype. However, in the article by Ko et al.,<a class="elsevierStyleCrossRef" href="#bib0185">37</a> patients treated with etanercept were more likely to develop plaque psoriasis, though this finding is probably not evaluable because, as commented above, the events in that study were exacerbations in almost half of cases.<elsevierMultimedia ident="fig0010"></elsevierMultimedia>The fact that the incidence of palmoplantar pustulosis in cases of psoriasis induced by TNF-α inhibitors is twice the incidence in the general population with psoriasis could suggest greater TNF-α expression in the eccrine glands of susceptible individuals.<a class="elsevierStyleCrossRef" href="#bib0335">67</a>In a review that only included patients with inflammatory bowel disease, the authors stated that these patients most commonly presented involvement of the palms and soles (43%) and of the scalp (42%).<a class="elsevierStyleCrossRef" href="#bib0135">27</a> However, in a recent series from Spain including 21 patients with inflammatory bowel disease, the most common form was plaque psoriasis, predominantly affecting the limbs (62%), though the trunk and the scalp were also affected.<a class="elsevierStyleCrossRef" href="#bib0165">33</a>Between 36% and 100% of patients, depending on the series, were receiving other psoriasis treatments concomitantly, including methotrexate and azathioprine, which have thus not been shown to be capable of preventing this type of reaction.<a class="elsevierStyleCrossRefs" href="#bib0125">25,27,33</a>The treatment most frequently used for this side effect has been topical therapy with corticosteroids, employed in almost 40% of cases according to the review by Ko et al.,<a class="elsevierStyleCrossRef" href="#bib0185">37</a> with no other changes in treatment. Resolution of the flare of psoriasis was reported in a quarter of patients. Topical therapy associated with withdrawal of the implicated anti-TNF-α agent was employed in a further 50%. The use of systemic psoriasis treatments, with or without interruption of the implicated agent, was more successful than the topical treatments (44% achieved resolution of the lesions). Only 15% of the patients who were changed to an alternative anti-TNF-α agent achieved a satisfactory response, while this figure rose to 64% among those who received treatments with a different mechanism of action. Those authors therefore considered that the essential action was to discontinue the anti-TNF-α agent. In mild or moderate cases, they recommended topical treatments or phototherapy in monotherapy or in combination with acitretin, depending on the response, whereas ciclosporin and methotrexate could be of benefit in acute or serious cases. In those cases in which the skin lesions did not resolve, no differences were found with regard to severity of the episode or type or distribution of the psoriasis compared with patients in whom the lesions resolved.In the review by Cullen et al.<a class="elsevierStyleCrossRef" href="#bib0135">27</a> of patients with inflammatory bowel disease, approximately 50% responded to topical therapy, as also found in the study by Collamer et al.,<a class="elsevierStyleCrossRef" href="#bib0125">25</a> in which the majority of patients responded to conservative treatment, without withdrawal of the implicated drug. In some patients with rheumatoid arthritis who developed psoriasis, whether of new onset or an exacerbation, interruption or dose reduction of the implicated drug caused the skin lesions to improve or disappear.<a class="elsevierStyleCrossRef" href="#bib0180">36</a>The more recent incorporation of other drugs with distinct mechanisms of action, such as ustekinumab, an anti-p40 agent, broadens the spectrum of treatments for this type of reaction. Spanish authors described a patient with Crohn disease who developed psoriasis with 2 anti-TNF-α drugs, infliximab and adalimumab. Ustekinumab, at a dose of 90mg every 8 weeks, achieved remission of the skin lesions, while control of the gastrointestinal disease was maintained with azathioprine and mesalazine.<a class="elsevierStyleCrossRef" href="#bib0235">47</a> In contrast, there has also been a case report in which, despite this treatment, an episode of palmoplantar pustulosis did not resolve or even got worse.<a class="elsevierStyleCrossRef" href="#bib0230">46</a> More recently, Puig et al.<a class="elsevierStyleCrossRef" href="#bib0215">43</a> reported their experience in another patient with psoriatic arthritis and performed a review of cases treated with ustekinumab. Those authors concluded that this drug could be a good therapeutic option in patients who develop paradoxical reactions with TNF-α inhibitors.Exacerbation of Previous PsoriasisAlthough exacerbations of previous psoriasis, with or without changes of morphology, have been more common in the daily clinical practice of the authors, exacerbations only accounted for 15% of cases included in the review of 207 patients by Collamer et al.<a class="elsevierStyleCrossRef" href="#bib0125">25</a> It is thus difficult to establish the characteristics of this type of reaction. Comparison of these patients with those with new onset psoriasis shows no significant difference according to sex; the agent most frequently implicated has been etanercept (62%), followed by the monoclonal antibodies (infliximab [23%] and adalimumab [15%]). Further studies are needed to clarify whether this difference is significant or arises because etanercept is the most widely used agent in dermatology. Collamer et al. considered that patients with psoriasis and psoriatic arthritis tended to develop lesions that differed from their previous psoriasis, most commonly presenting as guttate psoriasis. In 38% of such patients, the lesions resolved after discontinuation of the implicated agent and complete or partial remission was achieved in 53% while maintaining the implicated agent and adding other psoriasis treatments. The data on recurrence with other anti-TNF-α drugs are not evaluable jointly due to the heterogeneity of the patients and the short follow-up in some cases, and we will therefore discuss each subtype separately.Exacerbation of Previous Psoriasis With No Change in MorphologyIn 2010, Mourao et al.<a class="elsevierStyleCrossRef" href="#bib0275">55</a> published a review of 5 previously reported cases and added a further 3 cases to describe the exacerbation of previous psoriasis during treatment with an anti-TNF-α agent. In 1 of the patients, etanercept lost efficacy after 41 months and the skin disease subsequently worsened during treatment with adalimumab and infliximab. The latency period of these exacerbations has been very variable, with reports of 2 weeks to 32months after the start of exposure. There were no clear triggering factors.The possibility of reappearance of the skin lesions has also been described in patients with latent psoriasis who receive treatment with anti-TNF-α therapy to control rheumatoid arthritis. Kary et al.<a class="elsevierStyleCrossRef" href="#bib0180">36</a> described 3 patients, of whom 2 developed an episode of pustular psoriasis and the other of plaque psoriasis. In the opinion of those authors, the clinical improvement after withdrawal or dose reduction of the implicated drug supports the relationship with the drug.In some patients with psoriatic arthritis, the skin lesions have deteriorated while the arthritis has responded adequately to treatment.<a class="elsevierStyleCrossRef" href="#bib0275">55</a>Exacerbation of Previous Psoriasis With a Change in MorphologyFew data are available in the literature on exacerbations in which the morphology of the psoriasis changes during treatment with biologic agents. Our experience suggests that this type of reaction is more common than the literature to date would indicate. In 2007, a paper published by our department described 8 cases of new onset or exacerbation of psoriasis.<a class="elsevierStyleCrossRef" href="#bib0155">31</a> Six of those patients developed guttate psoriasis between 15 days and 18 months after starting treatment with etanercept for severe plaque psoriasis. None of the patients presented other triggers. Substitution of the biologic agent by ciclosporin was necessary to control the psoriasis in 1 of the patients due to a lack of response to topical corticosteroids. This type of paradoxical reaction is characterized by the sudden onset of small drop-like lesions predominantly in areas not previously affected by psoriasis, while the original plaques remain in remission (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>). These outbreaks should not be confused with a flare or exacerbation of the psoriasis of a different origin, not induced by the biologic agent; in these cases the new lesions are similar to the previous psoriasis lesions and appear in the same areas. Nor should they be confused with a flare-up of psoriasis, which is typically defined as a deterioration of the psoriasis of more than 125% compared to the baseline situation, or a change in morphology induced by the biological agent, but after its interruption. The changes in morphology to which we are referring in this section occur without discontinuation of the drug.<elsevierMultimedia ident="fig0015"></elsevierMultimedia>Mössner et al.<a class="elsevierStyleCrossRef" href="#bib0195">39</a> published a series of 5 patients (3 men and 2 women) who developed palmoplantar pustulosis during or after treatment with infliximab for plaque psoriasis. In 1 of their patients, the palmoplantar changes were associated with widespread pustular lesions. In 3 of the cases, there was a simultaneous exacerbation of the plaques. None of them had previously presented generalized or palmoplantar pustular psoriasis. The latency period varied between 3 and 40 weeks. Risk factors included infection in 1 patient and abrupt withdrawal of the infliximab in another. Lesion control by the addition of topical corticosteroids without the withdrawal of infliximab was only achieved in 1 patient.Spanish authors have reported the case of a patient on treatment with etanercept for plaque psoriasis. The patient developed pustular psoriasis 24hours after undergoing the tuberculin test, which could have been the trigger.<a class="elsevierStyleCrossRef" href="#bib0365">73</a>An erythrodermic form of psoriasis appearing after starting the drug, with a shorter latency period than other types of psoriasiform reaction, has occasionally been reported, and we have also observed this in our clinical practice. Santos-Juanes et al.<a class="elsevierStyleCrossRef" href="#bib0285">57</a> described 2 patients with plaque psoriasis who had previously received numerous psoriasis treatments with suboptimal responses. Those patients developed erythroderma during treatment with etanercept, but were subsequently stable during treatment with infliximab and adalimumab. However, both patients showed an improvement of more than 80% in the PASI (Psoriasis Area Severity Index) after 4 weeks of treatment with ustekinumab.<a class="elsevierStyleCrossRef" href="#bib0285">57</a>Histopathologic CharacteristicsHistological confirmation was only available for 39.4% of the 127 cases reviewed by Ko et al.<a class="elsevierStyleCrossRef" href="#bib0185">37</a> Some authors consider that these reactions present a histology compatible with palmoplantar pustulosis or psoriasis, indistinguishable from cases unrelated to anti-TNF-α therapy.<a class="elsevierStyleCrossRef" href="#bib0180">36</a>However, Seneschal et al.,<a class="elsevierStyleCrossRef" href="#bib0240">48</a> who described in detail the biopsies of their patients with psoriasiform reactions during anti-TNF-α therapy, did find some differences. Skin biopsy had been performed in 11 of their 13 cases. Clinically the lesions were typical small areas of plaque psoriasis, associated with palmoplantar pustulosis or keratoderma in 3 of them. In 5 patients, the authors observed a psoriasiform pattern with parakeratosis, hyperkeratosis, and acanthosis. Three of those 5 cases also presented a lichenoid infiltrate, and another 3 biopsies also showed a focal lichenoid pattern. Keratinocyte necrosis was detected in 3 patients. Seven of the samples had signs of spongiosis with epidermal edema, and a unilocular subcorneal pustule was observed in another case.Recently, Laga et al.<a class="elsevierStyleCrossRef" href="#bib0340">68</a> evaluated the histological spectrum of psoriasiform reactions associated with anti-TNF-α therapy in 16 biopsies from 9 patients. Those authors reported different histologic patterns, including lichen planus-type dermatitis, sterile pustular folliculitis, and a pattern similar to psoriasis. They concluded that correlation with the clinical findings was crucial to be able to make a diagnosis in this type of reaction. In our opinion, reactions that do not correspond clinically or histologically to palmoplantar pustulosis or psoriasis should not be included in the group of psoriasiform reactions induced by or associated with anti-TNF-α drugs.In favor of this opinion, other authors consider that the histologic findings of psoriasiform reactions are identical or very similar to the patient's psoriasis prior to anti-TNF-α therapy and differ from pustular drug reactions. They include epidermal hyperplasia, parakeratosis, epidermal lymphocyte infiltrates, dilated capillaries, and intraepidermal pustulosis.<a class="elsevierStyleCrossRef" href="#bib0265">53</a>Initial ManagementThe steps detailed below and in <a class="elsevierStyleCrossRefs" href="#tbl0015">Tables 3 and 4</a> should be followed for the management of any patient who develops a paradoxical psoriasiform reaction during treatment with any anti-TNF-α agent:<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015">•A detailed medical history should be obtained, including the following information:<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0020">∘Sociodemographic details.</li><li class="elsevierStyleListItem" id="lsti0025">∘Personal and family history of psoriasis.</li><li class="elsevierStyleListItem" id="lsti0030">∘Personal medical and surgical history, including a drug history, paying particular attention to the duration of drug treatments.</li><li class="elsevierStyleListItem" id="lsti0035">∘Details of the duration of the underlying disease that required the biologic therapy and concomitant or previous therapies administered.</li><li class="elsevierStyleListItem" id="lsti0040">∘Details of the duration of the current biologic treatment and the dose at the time of onset of the reaction.</li><li class="elsevierStyleListItem" id="lsti0045">∘Clinical course of the episode of psoriasis, the type or types of lesion, and history of similar rashes.</li><li class="elsevierStyleListItem" id="lsti0050">∘Information sufficient to exclude possible triggering factors, such as infection, stress, or the initiation of treatment with new drugs.</li></ul></li></ul><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="tbl0020"></elsevierMultimedia>The management of these patients is not well established. The following recommendations are based on our experience and on published reviews:<ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0055">∘Laboratory tests including complete blood count, liver and kidney function tests, antistreptolysin O antibody, and pharyngeal exudate at the start of the episode.</li><li class="elsevierStyleListItem" id="lsti0060">∘Except in clinically characteristic cases, 1 or several biopsies of the skin lesions. This is useful for diagnostic confirmation because, as some authors have stated, not all reactions described as psoriasiform are true psoriasis.</li></ul>The general treatment of paradoxical psoriasiform reactions is summarized in <a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>. However, based on our experience and on our review of the literature, we consider it useful to detail the treatment of each one of the subtypes:<ul class="elsevierStyleList" id="lis0025"><li class="elsevierStyleListItem" id="lsti0065">•In patients with new onset psoriasis during treatment with TNF-α inhibitors, the initial use of topical therapy with high-strength corticosteroids, vitamin D analogs, or combinations of the 2 is recommended. If this does not control the episode, 2 situations may arise. When it is necessary to continue the anti-TNF-α drug responsible for inducing the psoriasis because it adequately controls the patient's underlying nondermatologic disease without serious side effects, partial control of the skin lesions with topical therapy may be acceptable, with the possible addition of other therapies (phototherapy or systemic therapy). If it is not essential to continue the anti-TNF-α agent, it is best to substitute the implicated drug. Because of the possible class effect of the anti-TNF-α drugs, we recommend that the new therapy should act via a pathway that does not inhibit TNF-α in order to avoid a deterioration or recurrence of the skin disease.</li><li class="elsevierStyleListItem" id="lsti0070">•In case of erythrodermic psoriasis, the first step in all patients should be to substitute the drug by another with a rapid response, such as ciclosporin or ustekinumab, to treat the episode.</li><li class="elsevierStyleListItem" id="lsti0075">•In patients with a change in the morphology of the psoriasis, which is not serious in the majority of cases, the most widely used initial option is to continue using the same drug at the same dose and to prescribe topical therapy. If this is insufficient to control the episode, we recommend substitution of the first agent by another drug, preferably one with a different mechanism of action, as in cases of new onset psoriasis. Though possible, the option to add another systemic drug is, in our experience, less effective. This delays the substitution, which will be necessary in the large majority of patients in the end. However, therapeutic modalities such as phototherapy in monotherapy or in combination with acitretin in mild or moderate cases, or drugs such as ciclosporin or methotrexate in more serious cases, have been shown to be useful in some patients, as mentioned above in the text.</li></ul><elsevierMultimedia ident="tbl0025"></elsevierMultimedia>Ethical DisclosuresProtection of human and animal subjectsThe authors declare that no experiments were performed on humans or animals for this investigation.Confidentiality of dataThe authors declare that they followed their hospital's regulations regarding the publication of patient information and that written informed consent for voluntary participation was obtained for all patients.Right to privacy and informed consentThe authors declare that no private patient data are disclosed in this article.Conflicts of InterestDr E. Daudén undertakes or has undertaken the following activities: member of Advisory Boards, consultant, reception of grants, research support, participation in clinical trials and fees for lectures with the following pharmaceutical companies: Abbott, Astellas, Biogen, Centocor Ortho Biotech Inc, Galderma, Glaxo, Janssen-Cilag, Leo Pharma, MSD, Pfizer, Novartis, Stiefel, Wyeth Pharmaceuticals, 3M and Celgene.Dr. R. Navarro declares that she has no conflicts of interest." "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:2 [ "identificador" => "xres372204" "titulo" => "Abstract" ] 1 => array:2 [ "identificador" => "xpalclavsec351325" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres372203" "titulo" => "Resumen" ] 3 => array:2 [ "identificador" => "xpalclavsec351324" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Classification" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Pathogenesis of Psoriasiform Reactions" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "New Onset Psoriasis" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Exacerbation of Previous Psoriasis" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Exacerbation of Previous Psoriasis With No Change in Morphology" ] 3 => array:2 [ "identificador" => "sec0035" "titulo" => "Exacerbation of Previous Psoriasis With a Change in Morphology" ] ] ] 7 => array:2 [ "identificador" => "sec0040" "titulo" => "Histopathologic Characteristics" ] 8 => array:2 [ "identificador" => "sec0045" "titulo" => "Initial Management" ] 9 => array:3 [ "identificador" => "sec0050" "titulo" => "Ethical Disclosures" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0055" "titulo" => "Protection of human and animal subjects" ] 1 => array:2 [ "identificador" => "sec0060" "titulo" => "Confidentiality of data" ] 2 => array:2 [ "identificador" => "sec0065" "titulo" => "Right to privacy and informed consent" ] ] ] 10 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflicts of Interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2012-12-31" "fechaAceptado" => "2013-05-25" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec351325" "palabras" => array:8 [ 0 => "Psoriasis" 1 => "Palmoplantar pustulosis" 2 => "Guttate psoriasis" 3 => "Erythrodermia" 4 => "Tumor necrosis factor" 5 => "Psoriasiform reactions" 6 => "Adverse effects" 7 => "Induced psoriasis" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec351324" "palabras" => array:8 [ 0 => "Psoriasis" 1 => "Pustulosis palmoplantar" 2 => "Psoriasis guttata" 3 => "Eritrodermia" 4 => "Factor de necrosis tumoral" 5 => "Reacciones psoriasiformes" 6 => "Efectos adversos" 7 => "Psoriasis inducida" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "There have been reports of paradoxical induction or worsening of psoriasis during treatment with tumor necrosis factor (TNF) α agents (infliximab, etanercept, adalimumab, and certolizumab). It has been hypothesized that an imbalance between TNF-α and interferon α might have a role in the etiology and pathogenesis of these reactions. Paradoxical psoriasiform reactions can be divided clinically into de novo psoriasis and exacerbation of preexisting psoriasis. The first, which is more common and more extensively described in the literature, occurs in patients without a history of psoriasis who are receiving TNF-α therapy for another inflammatory disorder. The second can occur with or without changes in the morphology of the lesions. In this article, we review the literature on the clinical and histologic features of paradoxical psoriasiform reactions, analyze their clinical course and treatment, and propose a clinical management model for use in routine practice." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "Paradójicamente se han descrito casos de inducción o empeoramiento de una psoriasis durante el tratamiento con todos los agentes anti-factor de necrosis tumoral α (anti-TNFα) (infliximab, etanercept, adalimumab y certolizumab). Se ha postulado que la alteración del equilibrio entre el TNFα y el interferón α estaría implicada en su etiopatogenia. Clínicamente se distinguen varios patrones de reacciones psoriasiformes paradójicas: la psoriasis de novo en pacientes que no han presentado anteriormente esta enfermedad y que reciben este tratamiento por otra enfermedad inflamatoria, que es la más frecuente y la mejor descrita, y la exacerbación de una psoriasis preexistente durante la terapia anti-TNFα, que puede presentarse con o sin un cambio de morfología. En este trabajo realizamos una revisión de la literatura en relación con las características clínicas e histológicas de este tipo de reacciones, así como de su evolución y tratamiento, y planteamos un esquema de manejo en la práctica clínica." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Navarro R, Daudén E. Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo clínico. Actas Dermosifiliogr. 2014;105:752–761." ] ] "multimedia" => array:8 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 773 "Ancho" => 1559 "Tamanyo" => 88031 ] ] "descripcion" => array:1 [ "en" => "Classification of paradoxical psoriasiform reactions." ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 751 "Ancho" => 996 "Tamanyo" => 122653 ] ] "descripcion" => array:1 [ "en" => "Desquamating erythematous plaques with pustules on their surface. These developed on the palms of a patient on treatment with adalimumab for rheumatoid arthritis." ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1610 "Ancho" => 1001 "Tamanyo" => 179656 ] ] "descripcion" => array:1 [ "en" => "Patient with a history of plaque psoriasis who presented a sudden outbreak of small desquamating erythematous plaques with a drop-like appearance: A, On the abdomen. B, On the posterior aspect of the lower limbs." ] ] 3 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "Abbreviation: TNF, tumor necrosis factor." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Reference \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Type of Reaction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Underlying Disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Total No. of Patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">No. of Patients Receiving Each Anti-TNF-α Agent \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Kary et al. (2006)<a class="elsevierStyleCrossRef" href="#bib0180">36</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatoid arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 2; Etanercept, 3; Adalimumab, 4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Exacerbation with no morphological changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 2; Etanercept, 3; Adalimumab, 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Goiriz et al. (2006)<a class="elsevierStyleCrossRef" href="#bib0155">31</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatologic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 1; Adalimumab, 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Morphological changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Etanercept, 6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">De Gannes et al. (2007)<a class="elsevierStyleCrossRef" href="#bib0260">52</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatologic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 5; Etanercept, 6; Adalimumab, 4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Lee et al. (2007)<a class="elsevierStyleCrossRef" href="#bib0345">69</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatologic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 3; Etanercept, 2; Adalimumab, 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Exacerbation with no morphological changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Etanercept, 1; Adalimumab, 1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Seneschal et al. (2007)<a class="elsevierStyleCrossRef" href="#bib0240">48</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatologic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 7; Etanercept, 3; Adalimumab, 3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Harrison et al. (2009)<a class="elsevierStyleCrossRef" href="#bib0270">54</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatoid arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 6; Etanercept, 6; Adalimumab, 13 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cullen et al. (2011)<a class="elsevierStyleCrossRef" href="#bib0135">27</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inflammatory bowel disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 21; Adalimumab, 7; Certolizumab, 2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Guerra et al. (2012)<a class="elsevierStyleCrossRef" href="#bib0165">33</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inflammatory bowel disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 14; Adalimumab, 7 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab562533.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Review of the Literature: Articles With at Least 8 Patients who Developed Paradoxical Psoriasiform Reactions During Treatment With Tumor Necrosis Factor α Inhibitors." ] ] 4 => array:7 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "Abbreviation: TNF, tumor necrosis factor." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Reference \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Type of Reaction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Underlying Disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Total No. of Patients \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Percentage of Cases With the Different Anti-TNF-α Agents \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Collamer et al. (2008)<a class="elsevierStyleCrossRef" href="#bib0130">26</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset psoriasis and exacerbations with/without morphological changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatologic, gastrointestinal, and psoriatic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">104 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 53; Etanercept, 29; Adalimumab, 18 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Wollina et al. (2008)<a class="elsevierStyleCrossRef" href="#bib0045">9</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset psoriasis and exacerbations with/without morphological changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatologic, gastrointestinal, and psoriatic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">120 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 52.5; Etanercept, 30.8; Adalimumab, 21.7 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ko et al. (2009)<a class="elsevierStyleCrossRef" href="#bib0185">37</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset psoriasis and exacerbations with/without morphological changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatologic, gastrointestinal, and psoriatic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">127 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 55.1; Etanercept, 27.6; Adalimumab, 17.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Collamer et al. (2010)<a class="elsevierStyleCrossRef" href="#bib0125">25</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset psoriasis and exacerbations with/without morphological changes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Rheumatologic, gastrointestinal, and psoriatic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">207 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 59; Etanercept, 19; Adalimumab, 22 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cullen et al. (2011)<a class="elsevierStyleCrossRef" href="#bib0135">27</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gastrointestinal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">120 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 79; Adalimumab, 17; Certolizumab, 4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Denadai et al. (2012)<a class="elsevierStyleCrossRef" href="#bib0140">28</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New onset psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gastrointestinal \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">222 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Infliximab, 69.4; Adalimumab, 22.5; Certolizumab, 2.7;Not specified, 5.4 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab562537.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Most Relevant Revisions Published in the Literature." ] ] 5 => array:7 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Medical Background \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">History of the Underlying Disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Additional Tests \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Medical and surgical diseasesUsual medication \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical coursePrevious treatments \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Disease durationClinical formsPersonal/family backgroundExclude triggers \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Routine blood testsSkin biopsy for confirmation \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab562536.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Initial Management of Patients With New Onset Psoriasis During Treatment With Tumor Necrosis Factor α Inhibitors." ] ] 6 => array:7 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "Abbreviations: ASLO, antistreptolysin O antibody; TNF, tumor necrosis factor." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Medical Background \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Previous Form of Psoriasis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Episode of Psoriasis During anti-TNF-α Treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Additional Tests \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Medical and surgical diseasesUsual medication \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Clinical courseClinical formsPrevious treatments \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Disease durationClinical formsExclude triggers \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Routine blood tests, ASLO, and pharyngeal exudateSkin biopsy for confirmation \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab562534.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Initial Management of Patients With an Exacerbation of Previously Diagnosed Psoriasis During Treatment With Tumor Necrosis Factor α Inhibitors." ] ] 7 => array:7 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" style="border-bottom: 2px solid black">Treatment Sequence \t\t\t\t\t\t\n \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1. Add topical therapy (high-strength corticosteroids, vitamin D analogs, or combinations of the two) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2. Substitute the implicated drug (preferably by one with a different mechanism of action) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3. Combined therapy with another systemic treatment: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In mild or moderate cases: phototherapy and/or acitretin \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In severe cases: ciclosporin or methotrexate \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab562535.png" ] ] ] ] "descripcion" => array:1 [ "en" => "General Treatment of Paradoxical Psoriasiform Reactions." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:73 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F.O. Nestle" 1 => "D.H. Kaplan" 2 => "J. Barker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra0804595" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2009" "volumen" => "361" "paginaInicial" => "496" "paginaFinal" => "509" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19641206" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Triggering psoriasis: The role of infections and medications" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Fry" 1 => "B.S. Baker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clindermatol.2007.08.015" "Revista" => array:6 [ "tituloSerie" => "Clin Dermatol" "fecha" => "2007" "volumen" => "25" "paginaInicial" => "606" "paginaFinal" => "615" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18021899" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Integrated approach to comorbidity in patients with psoriasis" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Working Group on Psoriasis-associated comorbidities" "etal" => true "autores" => array:6 [ 0 => "E. Dauden" 1 => "S. Castaneda" 2 => "C. Suarez" 3 => "J. Garcia-Campayo" 4 => "A.J. Blasco" 5 => "M.D. Aguilar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0001-7310(12)70001-7" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2012" "volumen" => "103" "paginaInicial" => "1" "paginaFinal" => "64" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22364603" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Dauden" 1 => "S. Castaneda" 2 => "C. Suarez" 3 => "J. Garcia-Campayo" 4 => "A.J. Blasco" 5 => "M.D. Aguilar" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2012" "volumen" => "103" "paginaInicial" => "1" "paginaFinal" => "64" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Putting together the psoriasis puzzle: An update on developing targeted therapies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L.M. Johnson-Huang" 1 => "M.A. Lowes" 2 => "J.G. Krueger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1242/dmm.009092" "Revista" => array:6 [ "tituloSerie" => "Dis Model Mech" "fecha" => "2012" "volumen" => "5" "paginaInicial" => "423" "paginaFinal" => "433" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22730473" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.P. Leombruno" 1 => "T.R. Einarson" 2 => "E.C. Keystone" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2008.091025" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2009" "volumen" => "68" "paginaInicial" => "1136" "paginaFinal" => "1145" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18753157" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etanercept and infections" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Ribera" 1 => "L. Leal" 2 => "J. Luelmo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2010" "volumen" => "101" "paginaInicial" => "70" "paginaFinal" => "76" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20492884" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adverse effects of biological agents in the treatment of psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F. Rongioletti" 1 => "M. Burlando" 2 => "A. Parodi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/1153420-S0-000000000-00000" "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2010" "volumen" => "11" "paginaInicial" => "35" "paginaFinal" => "37" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20586505" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: First 120 cases from the literature including a series of six new patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "U. Wollina" 1 => "G. Hansel" 2 => "A. Koch" 3 => "J. Schonlebe" 4 => "E. Kostler" 5 => "G. Haroske" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Clin Dermatol" "fecha" => "2008" "volumen" => "9" "paginaInicial" => "1" "paginaFinal" => "14" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18092839" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.E. Moustou" 1 => "A. Matekovits" 2 => "C. Dessinioti" 3 => "C. Antoniou" 4 => "P.P. Sfikakis" 5 => "A.J. Stratigos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2008.10.060" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2009" "volumen" => "61" "paginaInicial" => "486" "paginaFinal" => "504" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19628303" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.M. Pariser" 1 => "C.L. Leonardi" 2 => "K. Gordon" 3 => "A.B. Gottlieb" 4 => "S. Tyring" 5 => "K.A. Papp" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2011.07.040" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2012" "volumen" => "67" "paginaInicial" => "245" "paginaFinal" => "256" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22015149" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase iiitrial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Menter" 1 => "S.K. Tyring" 2 => "K. Gordon" 3 => "A.B. Kimball" 4 => "C.L. Leonardi" 5 => "R.G. Langley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2007.09.010" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "106" "paginaFinal" => "115" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17936411" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.B. Gordon" 1 => "R.G. Langley" 2 => "C. Leonardi" 3 => "D. Toth" 4 => "M.A. Menter" 5 => "S. Kang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2006.05.027" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2006" "volumen" => "55" "paginaInicial" => "598" "paginaFinal" => "606" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17010738" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.B. Gordon" 1 => "A.B. Gottlieb" 2 => "C.L. Leonardi" 3 => "B.E. Elewski" 4 => "A. Wang" 5 => "A. Jahreis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/09546630500472838" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2006" "volumen" => "17" "paginaInicial" => "9" "paginaFinal" => "17" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16467018" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of infliximab vs methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Barker" 1 => "M. Hoffmann" 2 => "G. Wozel" 3 => "J.P. Ortonne" 4 => "H. Zheng" 5 => "H. van Hoogstraten" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2011.10615.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2011" "volumen" => "165" "paginaInicial" => "1109" "paginaFinal" => "1117" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21910713" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K. Reich" 1 => "A.D. Burden" 2 => "J.N. Eaton" 3 => "N.S. Hawkins" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2011.10583.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2012" "volumen" => "166" "paginaInicial" => "179" "paginaFinal" => "188" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21910698" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase iii, multicentre, double-blind trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Reich" 1 => "F.O. Nestle" 2 => "K. Papp" 3 => "J.P. Ortonne" 4 => "R. Evans" 5 => "C. Guzzo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(05)67566-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2005" "volumen" => "366" "paginaInicial" => "1367" "paginaFinal" => "1374" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16226614" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor necrosis factor-a antagonist-induced psoriasis: Yet another paradox in medicine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Aslanidis" 1 => "A. Pyrpasopoulou" 2 => "S. Douma" 3 => "A. Triantafyllou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-007-0789-5" "Revista" => array:6 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2008" "volumen" => "27" "paginaInicial" => "377" "paginaFinal" => "380" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17994192" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T. Bhutani" 1 => "J. Koo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/09546630903559814" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2011" "volumen" => "22" "paginaInicial" => "75" "paginaFinal" => "78" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20524874" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "S. Boms" 1 => "T. Sehr" 2 => "U. Jappe" 3 => "A. Enk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00105-007-1451-5" "Revista" => array:6 [ "tituloSerie" => "Hautarzt" "fecha" => "2008" "volumen" => "59" "paginaInicial" => "653" "paginaFinal" => "655" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18210001" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diffused suberitrodermic psoriasis induced by infliximab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "V. Bruzzese" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Reumatismo" "fecha" => "2007" "volumen" => "59" "paginaInicial" => "328" "paginaFinal" => "331" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18157290" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "V. Bruzzese" 1 => "J. Pepe" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Immunopathol Pharmacol" "fecha" => "2009" "volumen" => "22" "paginaInicial" => "235" "paginaFinal" => "238" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19309571" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Cavailhes" 1 => "S. Ingen-Housz-Oro" 2 => "S. Djennane" 3 => "M. Rafaa" 4 => "F. Fiszenson-Albala" 5 => "N. Weber" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Dermatol Venereol" "fecha" => "2007" "volumen" => "134" "paginaInicial" => "363" "paginaFinal" => "367" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17483757" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New-onset psoriasis associated with etanercept therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "L.A. Chen" 1 => "L.H. Su" 2 => "Y.J. Chang" 3 => "Y.L. Hsu" 4 => "T.H. Tsai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1346-8138.2010.00789.x" "Revista" => array:6 [ "tituloSerie" => "J Dermatol" "fecha" => "2010" "volumen" => "37" "paginaInicial" => "378" "paginaFinal" => "380" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20507411" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A.N. Collamer" 1 => "D.F. Battafarano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2010.04.003" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2010" "volumen" => "40" "paginaInicial" => "233" "paginaFinal" => "240" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20580412" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.N. Collamer" 1 => "K.T. Guerrero" 2 => "J.S. Henning" 3 => "D.F. Battafarano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23835" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "59" "paginaInicial" => "996" "paginaFinal" => "1001" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18576309" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "G. Cullen" 1 => "D. Kroshinsky" 2 => "A.S. Cheifetz" 3 => "J.R. Korzenik" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2036.2011.04866.x" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2011" "volumen" => "34" "paginaInicial" => "1318" "paginaFinal" => "1327" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21957906" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: A systematic literature review based on 222 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R. Denadai" 1 => "F.V. Teixeira" 2 => "F. Steinwurz" 3 => "R. Romiti" 4 => "R. Saad-Hossne" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.crohns.2012.08.007" "Revista" => array:6 [ "tituloSerie" => "J Crohns Colitis" "fecha" => "2013" "volumen" => "7" "paginaInicial" => "517" "paginaFinal" => "524" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22960136" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis induced by infliximab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "I.C. Fernandes" 1 => "T. Torres" 2 => "M. Sanches" 3 => "G. Velho" 4 => "P. Lago" 5 => "M. Selores" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Med Port" "fecha" => "2011" "volumen" => "24" "paginaInicial" => "709" "paginaFinal" => "712" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22856418" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: A retrospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Fouache" 1 => "V. Goeb" 2 => "N. Massy-Guillemant" 3 => "G. Avenel" 4 => "H. Bacquet-Deschryver" 5 => "M. Kozyreff-Meurice" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2009" "volumen" => "48" "paginaInicial" => "761" "paginaFinal" => "764" ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "R. Goiriz" 1 => "E. Dauden" 2 => "S. Perez-Gala" 3 => "G. Guhl" 4 => "A. Garcia-Diez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2230.2006.02315.x" "Revista" => array:6 [ "tituloSerie" => "Clin Exp Dermatol" "fecha" => "2007" "volumen" => "32" "paginaInicial" => "176" "paginaFinal" => "179" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17176269" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: A review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Grinblat" 1 => "M. Scheinberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.semarthrit.2007.05.004" "Revista" => array:6 [ "tituloSerie" => "Semin Arthritis Rheum" "fecha" => "2008" "volumen" => "37" "paginaInicial" => "251" "paginaFinal" => "255" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17640718" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Guerra" 1 => "A. Algaba" 2 => "J.L. Perez-Calle" 3 => "M. Chaparro" 4 => "I. Marin-Jimenez" 5 => "R. Garcia-Castellanos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.crohns.2011.10.007" "Revista" => array:6 [ "tituloSerie" => "J Crohns Colitis" "fecha" => "2012" "volumen" => "6" "paginaInicial" => "518" "paginaFinal" => "523" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22398059" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab and adalimumab-induced psoriasis in Crohn's disease: A paradoxical side effect" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Iborra" 1 => "B. Beltran" 2 => "G. Bastida" 3 => "M. Aguas" 4 => "P. Nos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.crohns.2010.11.001" "Revista" => array:6 [ "tituloSerie" => "J Crohns Colitis" "fecha" => "2011" "volumen" => "5" "paginaInicial" => "157" "paginaFinal" => "161" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21453886" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: Is it really a paradoxical side effect?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "C. Joyau" 1 => "G. Veyrac" 2 => "V. Dixneuf" 3 => "P. Jolliet" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2012" "volumen" => "30" "paginaInicial" => "700" "paginaFinal" => "706" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22935567" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Kary" 1 => "M. Worm" 2 => "H. Audring" 3 => "D. Huscher" 4 => "M. Renelt" 5 => "H. Sorensen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2005.037424" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2006" "volumen" => "65" "paginaInicial" => "405" "paginaFinal" => "407" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16150791" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.M. Ko" 1 => "A.B. Gottlieb" 2 => "J.F. Kerbleski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/09546630802441234" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2009" "volumen" => "20" "paginaInicial" => "100" "paginaFinal" => "108" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18923992" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis induced by infliximab in a patient suffering from Crohn's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E. Manni" 1 => "P. Barachini" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Immunopathol Pharmacol" "fecha" => "2009" "volumen" => "22" "paginaInicial" => "841" "paginaFinal" => "844" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19822070" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: Report on five cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Mossner" 1 => "D. Thaci" 2 => "J. Mohr" 3 => "S. Patzold" 4 => "H.P. Bertsch" 5 => "U. Kruger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00403-008-0831-8" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol Res" "fecha" => "2008" "volumen" => "300" "paginaInicial" => "101" "paginaFinal" => "105" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18239925" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "B.C. Park" 1 => "H.J. Lim" 2 => "B.S. Kim" 3 => "W.J. Lee" 4 => "W. Kim Do" 5 => "S.J. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5021/ad.2009.21.1.60" "Revista" => array:6 [ "tituloSerie" => "Ann Dermatol" "fecha" => "2009" "volumen" => "21" "paginaInicial" => "60" "paginaFinal" => "62" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20548859" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Passarini" 1 => "S.D. Infusino" 2 => "E. Barbieri" 3 => "E. Varotti" 4 => "P. Gionchetti" 5 => "F. Rizzello" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000107622" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2007" "volumen" => "215" "paginaInicial" => "295" "paginaFinal" => "300" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17911986" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biologics-induced autoimmune diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Perez-Alvarez" 1 => "M. Perez-de-Lis" 2 => "M. Ramos-Casals" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Curr Opin Rheumatol" "fecha" => "2012" "itemHostRev" => array:3 [ "pii" => "S1063458413009400" "estado" => "S300" "issn" => "10634584" ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: Case report and review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "L. Puig" …3 ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000339864" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2012" "volumen" => "225" "paginaInicial" => "14" "paginaFinal" => "17" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: A «class effect» of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/09546630902882089" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2010" "volumen" => "21" "paginaInicial" => "3" "paginaFinal" => "5" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A case of infliximab-induced psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Dermatol Online J" "fecha" => "2008" "volumen" => "14" "paginaInicial" => "9" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/RHU.0b013e31823262c3" "Revista" => array:6 [ "tituloSerie" => "J Clin Rheumatol" "fecha" => "2011" "volumen" => "17" "paginaInicial" => "385" "paginaFinal" => "386" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab in a patient with Crohn's disease and anti-TNF-alpha-induced psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.gastrohep.2011.04.003" "Revista" => array:6 [ "tituloSerie" => "Gastroenterol Hepatol" "fecha" => "2011" "volumen" => "34" "paginaInicial" => "546" "paginaFinal" => "550" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2009.09329.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2009" "volumen" => "161" "paginaInicial" => "1081" "paginaFinal" => "1088" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21233" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2005" "volumen" => "52" "paginaInicial" => "2513" "paginaFinal" => "2518" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab-induced psoriasis during therapy for Crohn's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.crohns.2011.12.007" "Revista" => array:6 [ "tituloSerie" => "J Crohns Colitis" "fecha" => "2012" "volumen" => "6" "paginaInicial" => "610" "paginaFinal" => "616" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Paradoxical adverse effects of anti-TNF-alpha treatment: Onset or exacerbation of cutaneous disorders" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/eci.09.18" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Clin Immunol" "fecha" => "2009" "volumen" => "5" "paginaInicial" => "421" "paginaFinal" => "431" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.143.2.223" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2007" "volumen" => "143" "paginaInicial" => "223" "paginaFinal" => "231" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biologic therapy (TNF-alpha antagonists)-induced psoriasis: A cytokine imbalance between TNF-alpha and IFN-alpha?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/RHU.0b013e318190dd88" "Revista" => array:6 [ "tituloSerie" => "J Clin Rheumatol" "fecha" => "2008" "volumen" => "14" "paginaInicial" => "353" "paginaFinal" => "356" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2007.087288" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2009" "volumen" => "68" "paginaInicial" => "209" "paginaFinal" => "215" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: Description of 3 cases and review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Exp Rheumatol" "fecha" => "2010" "volumen" => "28" "paginaInicial" => "408" "paginaFinal" => "410" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0280" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasiform skin reactions during treatment with etanercept" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2010" "volumen" => "101" "paginaInicial" => "106" "paginaFinal" => "110" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0285" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2010.09669.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2010" "volumen" => "162" "paginaInicial" => "1144" "paginaFinal" => "1146" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0290" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Review article: Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2036.2009.03955.x" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2009" "volumen" => "29" "paginaInicial" => "921" "paginaFinal" => "927" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0295" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-tumor necrosis factor-alpha-induced psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Rheumatol" "fecha" => "2006" "volumen" => "33" "paginaInicial" => "1411" "paginaFinal" => "1414" "link" => array:1 [ 0 => array:2 [ …2] ] "itemHostRev" => array:3 [ "pii" => "S1888441513000647" "estado" => "S300" "issn" => "18884415" ] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0300" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Occurrence of plantar pustular psoriasis during treatment with infliximab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ …2] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Cutan Med Surg" "fecha" => "2009" "volumen" => "13" "paginaInicial" => "40" "paginaFinal" => "42" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0305" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jbspin.2007.06.011" "Revista" => array:6 [ "tituloSerie" => "Joint Bone Spine" "fecha" => "2008" "volumen" => "75" "paginaInicial" => "315" "paginaFinal" => "318" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0310" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: Three further cases and current overview" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000095033" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2006" "volumen" => "213" "paginaInicial" => "182" "paginaFinal" => "186" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0315" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Dermatol Venereol" "fecha" => "2007" "volumen" => "134" "paginaInicial" => "337" "paginaFinal" => "342" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0320" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous adverse reaction to infliximab: Report of psoriasis developing in 3 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cutis" "fecha" => "2007" "volumen" => "80" "paginaInicial" => "231" "paginaFinal" => "237" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0325" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guttate psoriasis induced by infliximab in a child with Crohn's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ibd.20450" "Revista" => array:6 [ "tituloSerie" => "Inflamm Bowel Dis" "fecha" => "2008" "volumen" => "14" "paginaInicial" => "1462" "paginaFinal" => "1463" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0330" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Cutan Med Surg" "fecha" => "2011" "volumen" => "15" "paginaInicial" => "280" "paginaFinal" => "284" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0335" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infliximab can precipitate as well as worsen palmoplantar pustulosis: Possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2005.06977.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2005" "volumen" => "153" "paginaInicial" => "1243" "paginaFinal" => "1244" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0340" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/DAD.0b013e3181cb3ff7" "Revista" => array:6 [ "tituloSerie" => "Am J Dermatopathol" "fecha" => "2010" "volumen" => "32" "paginaInicial" => "568" "paginaFinal" => "573" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0345" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2007.07682.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2007" "volumen" => "156" "paginaInicial" => "486" "paginaFinal" => "491" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0350" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Dermatol Online J" "fecha" => "2011" "volumen" => "17" "paginaInicial" => "11" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0355" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Letter: Pathogenesis of tumour necrosis factor-alpha antagonists-induced psoriasiform lesions" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2036.2012.05126.x" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2012" "volumen" => "36" "paginaInicial" => "77" "paginaFinal" => "78" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0360" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: Should biological therapy be suspended?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arq Gastroenterol" "fecha" => "2012" "volumen" => "49" "paginaInicial" => "172" "paginaFinal" => "176" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0365" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Episode of pustular psoriasis after a tuberculin test in a patient with plaque psoriasis on treatment with etanercept" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2011.04.012" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2011" "volumen" => "102" "paginaInicial" => "828" "paginaFinal" => "830" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010500000008/v1_201409260034/S1578219014002133/v1_201409260034/en/main.assets" "Apartado" => array:4 [ "identificador" => "6151" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Practical Dermatology" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010500000008/v1_201409260034/S1578219014002133/v1_201409260034/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014002133?idApp=UINPBA000044"]

Statistics

Practical Dermatology

Clinical Management of Paradoxical Psoriasiform Reactions During TNF-α Therapy

Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo clínico

R. Navarro

Corresponding author

nat_eraa@hotmail.com

Corresponding author.

, E. Daudén

Departamento de Dermatología, Hospital Universitario La Princesa, Madrid, Spain

Read

12484

Times
was read the article

5493

Total PDF

6991

Total HTML

Share statistics

 array:24 [
  "pii" => "S1578219014002133"
  "issn" => "15782190"
  "doi" => "10.1016/j.adengl.2013.05.011"
  "estado" => "S300"
  "fechaPublicacion" => "2014-10-01"
  "aid" => "866"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
  "copyrightAnyo" => "2012"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "fla"
  "cita" => "Actas Dermosifiliogr. 2014;105:752-61"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2773
    "formatos" => array:3 [
      "EPUB" => 42
      "HTML" => 1353
      "PDF" => 1378
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0001731013002548"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2013.05.007"
      "estado" => "S300"
      "fechaPublicacion" => "2014-10-01"
      "aid" => "866"
      "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
      "documento" => "article"
      "crossmark" => 0
      "subdocumento" => "fla"
      "cita" => "Actas Dermosifiliogr. 2014;105:752-61"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 3681
        "formatos" => array:3 [
          "EPUB" => 2
          "HTML" => 2141
          "PDF" => 1538
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Dermatolog&#237;a Pr&#225;ctica</span>"
        "titulo" => "Reacciones psoriasiformes parad&#243;jicas durante el tratamiento con terapia anti-factor de necrosis tumoral&#46; Manejo cl&#237;nico"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "752"
            "paginaFinal" => "761"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Clinical Management of Paradoxical Psoriasiform Reactions During TNF- &#945; Therapy"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 773
                "Ancho" => 1559
                "Tamanyo" => 87735
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Clasificaci&#243;n de las reacciones psoriasiformes parad&#243;jicas&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "R&#46; Navarro, E&#46; Daud&#233;n"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "R&#46;"
                "apellidos" => "Navarro"
              ]
              1 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Daud&#233;n"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S1578219014002133"
          "doi" => "10.1016/j.adengl.2013.05.011"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014002133?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731013002548?idApp=UINPBA000044"
      "url" => "/00017310/0000010500000008/v1_201409260036/S0001731013002548/v1_201409260036/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S1578219014002030"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2013.09.009"
    "estado" => "S300"
    "fechaPublicacion" => "2014-10-01"
    "aid" => "904"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "ssu"
    "cita" => "Actas Dermosifiliogr. 2014;105:762-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1895
      "formatos" => array:3 [
        "EPUB" => 37
        "HTML" => 1242
        "PDF" => 616
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">History and Humanities in Dermatology</span>"
      "titulo" => "Syphilis and Human Experimentation From the First Appearance of the Disease to World War II&#58; A Historical Perspective and Reflections on Ethics"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "762"
          "paginaFinal" => "767"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Experimentaci&#243;n en s&#237;filis hasta la Segunda Guerra Mundial&#58; historia y reflexiones &#233;ticas"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0015"
          "etiqueta" => "Figure 3"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr3.jpeg"
              "Alto" => 723
              "Ancho" => 950
              "Tamanyo" => 115662
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Manchuria&#44; China&#58; Unit 731 physicians performing routine work&#46;</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Source of photograph&#58; British Broadcasting Corporation&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "E&#46; Cuerda-Galindo, X&#46; Sierra-Valent&#237;, E&#46; Gonz&#225;lez-L&#243;pez, F&#46; L&#243;pez-Mu&#241;oz"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Cuerda-Galindo"
            ]
            1 => array:2 [
              "nombre" => "X&#46;"
              "apellidos" => "Sierra-Valent&#237;"
            ]
            2 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Gonz&#225;lez-L&#243;pez"
            ]
            3 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "L&#243;pez-Mu&#241;oz"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S000173101300358X"
        "doi" => "10.1016/j.ad.2013.09.007"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101300358X?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014002030?idApp=UINPBA000044"
    "url" => "/15782190/0000010500000008/v1_201409260034/S1578219014002030/v1_201409260034/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S1578219014002157"
    "issn" => "15782190"
    "doi" => "10.1016/j.adengl.2013.09.010"
    "estado" => "S300"
    "fechaPublicacion" => "2014-10-01"
    "aid" => "911"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "ssu"
    "cita" => "Actas Dermosifiliogr. 2014;105:744-51"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1398
      "formatos" => array:3 [
        "EPUB" => 35
        "HTML" => 823
        "PDF" => 540
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
      "titulo" => "Vismodegib&#58; A Review"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "744"
          "paginaFinal" => "751"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Vismodegib&#58; revisi&#243;n"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1331
              "Ancho" => 2504
              "Tamanyo" => 231622
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Activation of the Hedgehog &#40;Hh&#41; pathway&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "V&#46; Ruiz-Salas, M&#46; Alegre, A&#46; L&#243;pez-Ferrer, J&#46;R&#46; Garc&#233;s"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "V&#46;"
              "apellidos" => "Ruiz-Salas"
            ]
            1 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Alegre"
            ]
            2 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "L&#243;pez-Ferrer"
            ]
            3 => array:2 [
              "nombre" => "J&#46;R&#46;"
              "apellidos" => "Garc&#233;s"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0001731013003712"
        "doi" => "10.1016/j.ad.2013.09.012"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731013003712?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014002157?idApp=UINPBA000044"
    "url" => "/15782190/0000010500000008/v1_201409260034/S1578219014002157/v1_201409260034/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Practical Dermatology</span>"
    "titulo" => "Clinical Management of Paradoxical Psoriasiform Reactions During TNF-&#945; Therapy"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "752"
        "paginaFinal" => "761"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "R&#46; Navarro, E&#46; Daud&#233;n"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "R&#46;"
            "apellidos" => "Navarro"
            "email" => array:1 [
              0 => "nat&#95;eraa&#64;hotmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "E&#46;"
            "apellidos" => "Daud&#233;n"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Universitario La Princesa&#44; Madrid&#44; Spain"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Reacciones psoriasiformes parad&#243;jicas durante el tratamiento con terapia anti-factor de necrosis tumoral&#46; Manejo cl&#237;nico"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 773
            "Ancho" => 1559
            "Tamanyo" => 88031
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Classification of paradoxical psoriasiform reactions&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Psoriasis&#44; a chronic inflammatory disease of unknown etiology&#44; affects approximately 2&#37; to 3&#37; of the population worldwide&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> It has been speculated that it could be the result of a combination of genetic and environmental factors&#59; a genetic predisposition does exist&#44; but it has not been possible to establish a classic Mendelian pattern of inheritance&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Numerous factors that trigger the onset of psoriasis or aggravate established psoriasis have been described&#44; including infections&#44; stress&#44; and drugs &#40;&#946;-blockers&#44; lithium&#44; &#8230;&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1&#44;2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Several hypotheses and models have been proposed to try to explain the pathogenesis of psoriasis&#59; these have led us to look not only at the skin&#44; but also at the multiple associated comorbid conditions&#44; such as psoriatic arthritis and cardiovascular disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;4</span></a> A unifying hypothesis is the model of the cytokine network&#44; which states that both external stimuli&#44; such as stress&#44; and endogenous ones&#44; such as viruses&#44; neuropeptides&#44; or drug ingestion&#44; can act as triggers that activate a cytokine cascade&#46; These cytokines include tumor necrosis factor &#40;TNF&#41; &#945;&#44; derived from antigen-presenting dendritic cells and keratinocytes&#44; and interferon &#40;IFN&#41; &#947; produced by activated type 1 helper T cells&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Around 90&#37; of individuals with psoriasis have the most common form&#44; the so-called plaque psoriasis or psoriasis vulgaris&#46; In the majority of cases&#44; the disease is mild and can be controlled with topical therapy&#46; However&#44; up to a third of patients develop moderate or severe psoriasis and require systemic therapy&#44; such as phototherapy&#44; acitretin&#44; methotrexate&#44; or ciclosporin&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> The toxicity of these drugs and the frequent lack of response to them has led to the appearance over the past 15 years of the so-called biologic therapies&#44; which act at different levels of the inflammatory cascade that gives rise to the plaques of psoriasis&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">The use of biologic therapy is increasing worldwide for the treatment not only of psoriasis&#44; but also of other chronic immune-mediated inflammatory diseases&#44; such as rheumatoid arthritis&#44; ankylosing spondylitis&#44; and inflammatory bowel disease&#46; At the present time&#44; the most widely employed drugs are those that inhibit TNF-&#945; &#40;infliximab&#44; etanercept&#44; and adalimumab&#41;&#44; though a number of side effects have been reported during their use&#44; including infections&#44; reactivation of latent tuberculosis&#44; demyelinating diseases&#44; and congestive heart failure&#46;<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6&#8211;8</span></a></p><p id="par0330" class="elsevierStylePara elsevierViewall">It has been reported that the cutaneous side effects of anti-TNF-&#945; therapy are more prevalent than was previously thought&#46;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> These effects include reactions at the site of infusion or injection&#44; skin infections&#44; eczema&#44; and even psoriasis or psoriasiform reactions&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> Though paradoxical &#40;as these drugs are of demonstrated efficacy in the treatment of psoriasis<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11&#8211;17</span></a>&#41;&#44; case reports and some case series describe patients with exacerbations of their psoriasis or even the new onset of distinct subtypes of psoriasis during anti-TNF-&#945; therapy&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#44;10&#44;18&#8211;73</span></a> The most relevant articles and reviews are summarized in <a class="elsevierStyleCrossRefs" href="#tbl0005">Tables 1 and 2</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Moustou et al&#46;<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> published a literature review in which they established the strength of the association between published side effects and the use of 1 or more anti-TNF-&#945; agents&#44; classifying the association as poor&#44; moderate&#44; strong&#44; or definitive&#46; The authors used descriptions of the side effects in meta-analyses&#44; randomized trials&#44; retrospective or prospective studies&#44; case series&#44; and case reports&#46; They analyzed the number of anti-TNF-&#945; agents implicated&#44; the number of distinct inflammatory diseases in which the side effect had occurred during treatment with anti-TNF-&#945; drugs&#44; and the clinical course after withdrawal and reintroduction of the drug&#46; The authors not only described the clinical manifestations of these cutaneous reactions&#44; but they also established that there was a strong relationship between anti-TNF-&#945; therapy and new onset psoriasis or psoriasiform reactions&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Classification</span><p id="par0040" class="elsevierStylePara elsevierViewall">Distinct patterns of paradoxical psoriasiform reactions can be distinguished during treatment with TNF-&#945;-inhibitors &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0045" class="elsevierStylePara elsevierViewall">The induction of new onset psoriasis&#44; which is the appearance of psoriasis lesions in patients who have not previously been diagnosed with this disease and who are receiving anti-TNF-&#945; treatment for another inflammatory disease&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0050" class="elsevierStylePara elsevierViewall">An exacerbation of pre-existing psoriasis&#44; with or without morphologic differences&#44; during anti-TNF-&#945; therapy&#46;</p></li></ul></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Pathogenesis of Psoriasiform Reactions</span><p id="par0055" class="elsevierStylePara elsevierViewall">The pathophysiology of the induction or exacerbation of psoriasis during treatment with TNF-&#945; inhibitors is still unknown&#46; A number of theories have been proposed&#44; such as a disruption of the balance between TNF-&#945; and IFN-&#945;&#44; activation of self-reactive T lymphocytes&#44; wrong diagnosis&#44; natural course of the primary disease&#44; or infections that trigger such reactions&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#44;10&#44;25&#44;37</span></a> In their article on the pathogenesis of psoriasiform reactions&#44; Collamer et al&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> explained that a disruption of cytokine balance could lead to increased IFN-&#945; production by dendritic cells in genetically predisposed individuals&#44; and that genetic polymorphisms could play a role in this paradoxical reaction secondary to TNF-&#945; blockade&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">De Gannes et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a> in an article published in 2007&#44; demonstrated that patients who developed new onset psoriasis during treatment with anti-TNF-&#945; agents presented elevated expression of antimyxovirus-resistance protein A &#40;MxA&#41;&#44; an adenosine triphosphatase that is selectively induced in response to type 1 IFN and could be used as a surrogate marker of lesional type 1 IFN activity&#46; In that study&#44; staining for MxA in biopsies from patients receiving treatment with anti-TNF was more intense than in the biopsies from patients with psoriasis vulgaris not associated with anti-TNF-&#945; therapy&#46; Such an increase would favor the formation of psoriasis lesions in predisposed individuals&#46; Subsequently&#44; Seneschal et al&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a> described 13 patients who developed distinct subtypes of psoriasis&#59; biopsies from those patients revealed increased production of MxA protein compared with biopsies from healthy skin or from noninduced psoriasis lesions&#46; Those authors concluded that increased IFN-&#945; levels associated with cytokine imbalance &#40;both situations caused by TNF-&#945; inhibition&#41; could play an important role in the appearance of this type of reaction&#44; which they considered to be a drug reaction rather than true psoriasis&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">However&#44; another study found no differences between induced and noninduced psoriasis on immunohistochemical analysis with staining for the mRNA of IFN and TNF-&#945; and for vascular endothelial growth factor&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">Some authors believe that there must be a genetic predisposition&#44; as the majority of patients receiving anti-TNF-&#945; therapy for a wide range of diseases do not develop psoriasis&#46; Some environmental factor may also be exerting an effect&#44; as the latency between the initiation of treatment and the appearance of psoriasis is very variable &#40;from days to years&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;27&#44;37</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">This wide variability makes it difficult to establish a causal relationship in some cases&#46; It is therefore important to exclude any other factor that could trigger the appearance of psoriasis&#44; such as infection&#44; trauma&#44; stress&#44; or new drugs&#46;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">According to some authors&#44; paradoxical psoriasiform reactions are the result of a class effect&#44; as cases have been reported with all 3 classic TNF-&#945; inhibitors &#40;infliximab&#44; etanercept&#44; and adalimumab&#41;&#44; in frequencies proportional to the prevalence of their use&#46;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> More recently&#44; the phenomenon has been described in patients treated with certolizumab&#44; a newer anti-TNF-&#945; agent&#46; In the literature&#44; we have found a review article describing 6 cases related to this drug in patients with inflammatory bowel disease&#44; in addition to another case from our own records&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> Recurrence after the administration of a distinct anti-TNF-&#945; drug supports the class effect theory&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;27&#44;33&#44;36&#44;37&#44;55</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Reports have also been published of cases of new onset psoriasis or exacerbations during treatment with psoriasis drugs other than the TNF-&#945; inhibitors&#44; including drugs such as efalizumab&#44; ciclosporin&#44; and anthralin&#44; as well as after phototherapy or glucocorticoid withdrawal&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">55</span></a> Furthermore&#44; other biologic agents have been implicated&#44; such as abatacept in a patient who developed guttate psoriasis during treatment with etanercept and&#44; 2 years later&#44; a further episode with the same morphology during treatment with abatacept&#46;<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">70</span></a> For Rallis et al&#46;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a> this suggests a gap in our understanding of the pathophysiology of psoriasis and of the exact mechanism by which some of these drugs act&#46;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a></p><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">New Onset Psoriasis</span><p id="par0090" class="elsevierStylePara elsevierViewall">The large majority of published cases refer to new onset psoriasis&#44; particularly in patients with rheumatologic diseases&#46; Based on published studies&#44; it has been established that the prevalence of psoriasis during anti-TNF-&#945; therapy is between 0&#46;6&#37; and 5&#46;3&#37;&#44; depending on differences between the populations studied and treated&#46;<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">27&#44;54</span></a> In a recent article on psoriasis induced during treatment with anti-TNF-&#945; drugs for inflammatory bowel disease&#44; the reported prevalence was 1&#46;62&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Data coming from the larger series and from literature reviews are not particularly homogeneous&#46; This&#44; and the fact that not all cases will have been published&#44; could lead to biased conclusions&#46; In a recent review article that included 207 cases &#40;after excluding patients with any known trigger&#41;&#44; it was reported that 85&#37; of patients had developed new onset psoriasis&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">There is a female predominance &#40;2 women to 1 man&#41;&#44; due to cases associated with rheumatoid arthritis and inflammatory bowel disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;37</span></a> Series of patients with rheumatoid arthritis show the greatest difference&#44; up to 5&#46;3 women to 1 man&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> When all cases are included&#44; the mean age at onset is 44&#46;9 years &#40;range&#44; 13-78 years&#41;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a>&#59; however&#44; the mean age among patients with gastrointestinal disease is lower &#40;30 years&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Looking at all cases that were fully reviewed&#44; the drug most commonly implicated was infliximab&#44; accounting for 55&#46;1&#37; to 59&#37; cases&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;37</span></a> In their review of the literature&#44; Ko et al&#46;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> identified 127 cases reported up to September 2007&#46; Those authors stated that the second most common drug was etanercept &#40;27&#46;6&#37;&#41; and&#44; finally&#44; adalimumab &#40;17&#46;3&#37;&#41;&#46; However&#44; in a more recent series by Collamer et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> 22&#37; of all cases were on treatment with adalimumab and 17&#37; with etanercept&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Cullen et al&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> performed a review of 120 cases&#44; including 30 cases of their own&#44; with the additional inclusion criterion of a history of inflammatory bowel disease&#46; Their results indicated that 79&#37; had received infliximab&#44; 17&#37; adalimumab&#44; and 4&#37; the new drug&#44; certolizumab&#59; it must be taken into account that etanercept is not approved for use in inflammatory bowel disease&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Those percentages were proportional to the use of each one of the drugs&#46; In contrast&#44; in a series of patients from the British Society for Rheumatology Biologics Register&#44; with a description of 25 cases of new onset psoriasis in a cohort of 9826 patients with AR&#44; 13 were on treatment with adalimumab&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> That group of 25 patients was compared with another group formed of patients receiving treatment with disease-modifying antirheumatic drugs&#59; none of the patients in the latter group developed psoriasis after a follow-up of 2&#46;81 years&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">The latency is very variable&#44; from days to 80 months&#44; with a mean of 10&#46;5 months&#46; In the review by Ko et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> the latency was shorter in patients treated with etanercept&#44; although 42&#46;9&#37; were exacerbations of previously known psoriasis rather than new onset psoriasis&#46; Other authors&#44; such as Chen et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> who published a review of cases arising with etanercept&#44; have also reported a shorter latency with this drug&#46; In the 25 patients included in the review by those authors&#44; the mean latency was 3&#46;5 months after the initiation of treatment&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">More than half of published cases have occurred in patients with rheumatologic diseases&#44; particularly rheumatoid arthritis&#44; which accounts for 42&#46;5&#37; to 50&#46;4&#37; of cases&#44; depending on the study&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;37</span></a></p><p id="par0130" class="elsevierStylePara elsevierViewall">Overall&#44; the cases reported have been of any type of psoriasis and at any site&#58; vulgaris&#44; guttatate&#44; inverse&#44; or generalized or palmoplantar pustulosis &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>&#41;&#59; the latter subtype was the most common form in the larger series and reviews&#46;<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9&#44;25&#44;37</span></a> Adalimumab has been reported to be the drug most frequently implicated in palmoplantar pustulosis&#44; and more than half of the paradoxical reactions described with this drug are of this subtype&#46; However&#44; in the article by Ko et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> patients treated with etanercept were more likely to develop plaque psoriasis&#44; though this finding is probably not evaluable because&#44; as commented above&#44; the events in that study were exacerbations in almost half of cases&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0135" class="elsevierStylePara elsevierViewall">The fact that the incidence of palmoplantar pustulosis in cases of psoriasis induced by TNF-&#945; inhibitors is twice the incidence in the general population with psoriasis could suggest greater TNF-&#945; expression in the eccrine glands of susceptible individuals&#46;<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">67</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall">In a review that only included patients with inflammatory bowel disease&#44; the authors stated that these patients most commonly presented involvement of the palms and soles &#40;43&#37;&#41; and of the scalp &#40;42&#37;&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> However&#44; in a recent series from Spain including 21 patients with inflammatory bowel disease&#44; the most common form was plaque psoriasis&#44; predominantly affecting the limbs &#40;62&#37;&#41;&#44; though the trunk and the scalp were also affected&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Between 36&#37; and 100&#37; of patients&#44; depending on the series&#44; were receiving other psoriasis treatments concomitantly&#44; including methotrexate and azathioprine&#44; which have thus not been shown to be capable of preventing this type of reaction&#46;<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25&#44;27&#44;33</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">The treatment most frequently used for this side effect has been topical therapy with corticosteroids&#44; employed in almost 40&#37; of cases according to the review by Ko et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> with no other changes in treatment&#46; Resolution of the flare of psoriasis was reported in a quarter of patients&#46; Topical therapy associated with withdrawal of the implicated anti-TNF-&#945; agent was employed in a further 50&#37;&#46; The use of systemic psoriasis treatments&#44; with or without interruption of the implicated agent&#44; was more successful than the topical treatments &#40;44&#37; achieved resolution of the lesions&#41;&#46; Only 15&#37; of the patients who were changed to an alternative anti-TNF-&#945; agent achieved a satisfactory response&#44; while this figure rose to 64&#37; among those who received treatments with a different mechanism of action&#46; Those authors therefore considered that the essential action was to discontinue the anti-TNF-&#945; agent&#46; In mild or moderate cases&#44; they recommended topical treatments or phototherapy in monotherapy or in combination with acitretin&#44; depending on the response&#44; whereas ciclosporin and methotrexate could be of benefit in acute or serious cases&#46; In those cases in which the skin lesions did not resolve&#44; no differences were found with regard to severity of the episode or type or distribution of the psoriasis compared with patients in whom the lesions resolved&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">In the review by Cullen et al&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> of patients with inflammatory bowel disease&#44; approximately 50&#37; responded to topical therapy&#44; as also found in the study by Collamer et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> in which the majority of patients responded to conservative treatment&#44; without withdrawal of the implicated drug&#46; In some patients with rheumatoid arthritis who developed psoriasis&#44; whether of new onset or an exacerbation&#44; interruption or dose reduction of the implicated drug caused the skin lesions to improve or disappear&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">The more recent incorporation of other drugs with distinct mechanisms of action&#44; such as ustekinumab&#44; an anti-p40 agent&#44; broadens the spectrum of treatments for this type of reaction&#46; Spanish authors described a patient with Crohn disease who developed psoriasis with 2 anti-TNF-&#945; drugs&#44; infliximab and adalimumab&#46; Ustekinumab&#44; at a dose of 90<span class="elsevierStyleHsp" style=""></span>mg every 8 weeks&#44; achieved remission of the skin lesions&#44; while control of the gastrointestinal disease was maintained with azathioprine and mesalazine&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">47</span></a> In contrast&#44; there has also been a case report in which&#44; despite this treatment&#44; an episode of palmoplantar pustulosis did not resolve or even got worse&#46;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">46</span></a> More recently&#44; Puig et al&#46;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">43</span></a> reported their experience in another patient with psoriatic arthritis and performed a review of cases treated with ustekinumab&#46; Those authors concluded that this drug could be a good therapeutic option in patients who develop paradoxical reactions with TNF-&#945; inhibitors&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Exacerbation of Previous Psoriasis</span><p id="par0165" class="elsevierStylePara elsevierViewall">Although exacerbations of previous psoriasis&#44; with or without changes of morphology&#44; have been more common in the daily clinical practice of the authors&#44; exacerbations only accounted for 15&#37; of cases included in the review of 207 patients by Collamer et al&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> It is thus difficult to establish the characteristics of this type of reaction&#46; Comparison of these patients with those with new onset psoriasis shows no significant difference according to sex&#59; the agent most frequently implicated has been etanercept &#40;62&#37;&#41;&#44; followed by the monoclonal antibodies &#40;infliximab &#91;23&#37;&#93; and adalimumab &#91;15&#37;&#93;&#41;&#46; Further studies are needed to clarify whether this difference is significant or arises because etanercept is the most widely used agent in dermatology&#46; Collamer et al&#46; considered that patients with psoriasis and psoriatic arthritis tended to develop lesions that differed from their previous psoriasis&#44; most commonly presenting as guttate psoriasis&#46; In 38&#37; of such patients&#44; the lesions resolved after discontinuation of the implicated agent and complete or partial remission was achieved in 53&#37; while maintaining the implicated agent and adding other psoriasis treatments&#46; The data on recurrence with other anti-TNF-&#945; drugs are not evaluable jointly due to the heterogeneity of the patients and the short follow-up in some cases&#44; and we will therefore discuss each subtype separately&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Exacerbation of Previous Psoriasis With No Change in Morphology</span><p id="par0170" class="elsevierStylePara elsevierViewall">In 2010&#44; Mourao et al&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">55</span></a> published a review of 5 previously reported cases and added a further 3 cases to describe the exacerbation of previous psoriasis during treatment with an anti-TNF-&#945; agent&#46; In 1 of the patients&#44; etanercept lost efficacy after 41 months and the skin disease subsequently worsened during treatment with adalimumab and infliximab&#46; The latency period of these exacerbations has been very variable&#44; with reports of 2 weeks to 32<span class="elsevierStyleHsp" style=""></span>months after the start of exposure&#46; There were no clear triggering factors&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">The possibility of reappearance of the skin lesions has also been described in patients with latent psoriasis who receive treatment with anti-TNF-&#945; therapy to control rheumatoid arthritis&#46; Kary et al&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a> described 3 patients&#44; of whom 2 developed an episode of pustular psoriasis and the other of plaque psoriasis&#46; In the opinion of those authors&#44; the clinical improvement after withdrawal or dose reduction of the implicated drug supports the relationship with the drug&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">In some patients with psoriatic arthritis&#44; the skin lesions have deteriorated while the arthritis has responded adequately to treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">55</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Exacerbation of Previous Psoriasis With a Change in Morphology</span><p id="par0185" class="elsevierStylePara elsevierViewall">Few data are available in the literature on exacerbations in which the morphology of the psoriasis changes during treatment with biologic agents&#46; Our experience suggests that this type of reaction is more common than the literature to date would indicate&#46; In 2007&#44; a paper published by our department described 8 cases of new onset or exacerbation of psoriasis&#46;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a> Six of those patients developed guttate psoriasis between 15 days and 18 months after starting treatment with etanercept for severe plaque psoriasis&#46; None of the patients presented other triggers&#46; Substitution of the biologic agent by ciclosporin was necessary to control the psoriasis in 1 of the patients due to a lack of response to topical corticosteroids&#46; This type of paradoxical reaction is characterized by the sudden onset of small drop-like lesions predominantly in areas not previously affected by psoriasis&#44; while the original plaques remain in remission &#40;<a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>&#41;&#46; These outbreaks should not be confused with a flare or exacerbation of the psoriasis of a different origin&#44; not induced by the biologic agent&#59; in these cases the new lesions are similar to the previous psoriasis lesions and appear in the same areas&#46; Nor should they be confused with a flare-up of psoriasis&#44; which is typically defined as a deterioration of the psoriasis of more than 125&#37; compared to the baseline situation&#44; or a change in morphology induced by the biological agent&#44; but after its interruption&#46; The changes in morphology to which we are referring in this section occur without discontinuation of the drug&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0190" class="elsevierStylePara elsevierViewall">M&#246;ssner et al&#46;<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a> published a series of 5 patients &#40;3 men and 2 women&#41; who developed palmoplantar pustulosis during or after treatment with infliximab for plaque psoriasis&#46; In 1 of their patients&#44; the palmoplantar changes were associated with widespread pustular lesions&#46; In 3 of the cases&#44; there was a simultaneous exacerbation of the plaques&#46; None of them had previously presented generalized or palmoplantar pustular psoriasis&#46; The latency period varied between 3 and 40 weeks&#46; Risk factors included infection in 1 patient and abrupt withdrawal of the infliximab in another&#46; Lesion control by the addition of topical corticosteroids without the withdrawal of infliximab was only achieved in 1 patient&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">Spanish authors have reported the case of a patient on treatment with etanercept for plaque psoriasis&#46; The patient developed pustular psoriasis 24<span class="elsevierStyleHsp" style=""></span>hours after undergoing the tuberculin test&#44; which could have been the trigger&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">73</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">An erythrodermic form of psoriasis appearing after starting the drug&#44; with a shorter latency period than other types of psoriasiform reaction&#44; has occasionally been reported&#44; and we have also observed this in our clinical practice&#46; Santos-Juanes et al&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a> described 2 patients with plaque psoriasis who had previously received numerous psoriasis treatments with suboptimal responses&#46; Those patients developed erythroderma during treatment with etanercept&#44; but were subsequently stable during treatment with infliximab and adalimumab&#46; However&#44; both patients showed an improvement of more than 80&#37; in the PASI &#40;Psoriasis Area Severity Index&#41; after 4 weeks of treatment with ustekinumab&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a></p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Histopathologic Characteristics</span><p id="par0205" class="elsevierStylePara elsevierViewall">Histological confirmation was only available for 39&#46;4&#37; of the 127 cases reviewed by Ko et al&#46;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> Some authors consider that these reactions present a histology compatible with palmoplantar pustulosis or psoriasis&#44; indistinguishable from cases unrelated to anti-TNF-&#945; therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall">However&#44; Seneschal et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a> who described in detail the biopsies of their patients with psoriasiform reactions during anti-TNF-&#945; therapy&#44; did find some differences&#46; Skin biopsy had been performed in 11 of their 13 cases&#46; Clinically the lesions were typical small areas of plaque psoriasis&#44; associated with palmoplantar pustulosis or keratoderma in 3 of them&#46; In 5 patients&#44; the authors observed a psoriasiform pattern with parakeratosis&#44; hyperkeratosis&#44; and acanthosis&#46; Three of those 5 cases also presented a lichenoid infiltrate&#44; and another 3 biopsies also showed a focal lichenoid pattern&#46; Keratinocyte necrosis was detected in 3 patients&#46; Seven of the samples had signs of spongiosis with epidermal edema&#44; and a unilocular subcorneal pustule was observed in another case&#46;</p><p id="par0215" class="elsevierStylePara elsevierViewall">Recently&#44; Laga et al&#46;<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">68</span></a> evaluated the histological spectrum of psoriasiform reactions associated with anti-TNF-&#945; therapy in 16 biopsies from 9 patients&#46; Those authors reported different histologic patterns&#44; including lichen planus-type dermatitis&#44; sterile pustular folliculitis&#44; and a pattern similar to psoriasis&#46; They concluded that correlation with the clinical findings was crucial to be able to make a diagnosis in this type of reaction&#46; In our opinion&#44; reactions that do not correspond clinically or histologically to palmoplantar pustulosis or psoriasis should not be included in the group of psoriasiform reactions induced by or associated with anti-TNF-&#945; drugs&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">In favor of this opinion&#44; other authors consider that the histologic findings of psoriasiform reactions are identical or very similar to the patient&#39;s psoriasis prior to anti-TNF-&#945; therapy and differ from pustular drug reactions&#46; They include epidermal hyperplasia&#44; parakeratosis&#44; epidermal lymphocyte infiltrates&#44; dilated capillaries&#44; and intraepidermal pustulosis&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Initial Management</span><p id="par0225" class="elsevierStylePara elsevierViewall">The steps detailed below and in <a class="elsevierStyleCrossRefs" href="#tbl0015">Tables 3 and 4</a> should be followed for the management of any patient who develops a paradoxical psoriasiform reaction during treatment with any anti-TNF-&#945; agent&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">&#8226;</span><p id="par0230" class="elsevierStylePara elsevierViewall">A detailed medical history should be obtained&#44; including the following information&#58;<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">&#8728;</span><p id="par0235" class="elsevierStylePara elsevierViewall">Sociodemographic details&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">&#8728;</span><p id="par0240" class="elsevierStylePara elsevierViewall">Personal and family history of psoriasis&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">&#8728;</span><p id="par0245" class="elsevierStylePara elsevierViewall">Personal medical and surgical history&#44; including a drug history&#44; paying particular attention to the duration of drug treatments&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">&#8728;</span><p id="par0250" class="elsevierStylePara elsevierViewall">Details of the duration of the underlying disease that required the biologic therapy and concomitant or previous therapies administered&#46;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">&#8728;</span><p id="par0255" class="elsevierStylePara elsevierViewall">Details of the duration of the current biologic treatment and the dose at the time of onset of the reaction&#46;</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">&#8728;</span><p id="par0260" class="elsevierStylePara elsevierViewall">Clinical course of the episode of psoriasis&#44; the type or types of lesion&#44; and history of similar rashes&#46;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">&#8728;</span><p id="par0265" class="elsevierStylePara elsevierViewall">Information sufficient to exclude possible triggering factors&#44; such as infection&#44; stress&#44; or the initiation of treatment with new drugs&#46;</p></li></ul></p></li></ul></p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0270" class="elsevierStylePara elsevierViewall">The management of these patients is not well established&#46; The following recommendations are based on our experience and on published reviews&#58;<ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">&#8728;</span><p id="par0275" class="elsevierStylePara elsevierViewall">Laboratory tests including complete blood count&#44; liver and kidney function tests&#44; antistreptolysin O antibody&#44; and pharyngeal exudate at the start of the episode&#46;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">&#8728;</span><p id="par0280" class="elsevierStylePara elsevierViewall">Except in clinically characteristic cases&#44; 1 or several biopsies of the skin lesions&#46; This is useful for diagnostic confirmation because&#44; as some authors have stated&#44; not all reactions described as psoriasiform are true psoriasis&#46;</p></li></ul></p><p id="par0285" class="elsevierStylePara elsevierViewall">The general treatment of paradoxical psoriasiform reactions is summarized in <a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>&#46; However&#44; based on our experience and on our review of the literature&#44; we consider it useful to detail the treatment of each one of the subtypes&#58;<ul class="elsevierStyleList" id="lis0025"><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">&#8226;</span><p id="par0290" class="elsevierStylePara elsevierViewall">In patients with new onset psoriasis during treatment with TNF-&#945; inhibitors&#44; the initial use of topical therapy with high-strength corticosteroids&#44; vitamin D analogs&#44; or combinations of the 2 is recommended&#46; If this does not control the episode&#44; 2 situations may arise&#46; When it is necessary to continue the anti-TNF-&#945; drug responsible for inducing the psoriasis because it adequately controls the patient&#39;s underlying nondermatologic disease without serious side effects&#44; partial control of the skin lesions with topical therapy may be acceptable&#44; with the possible addition of other therapies &#40;phototherapy or systemic therapy&#41;&#46; If it is not essential to continue the anti-TNF-&#945; agent&#44; it is best to substitute the implicated drug&#46; Because of the possible class effect of the anti-TNF-&#945; drugs&#44; we recommend that the new therapy should act via a pathway that does not inhibit TNF-&#945; in order to avoid a deterioration or recurrence of the skin disease&#46;</p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">&#8226;</span><p id="par0295" class="elsevierStylePara elsevierViewall">In case of erythrodermic psoriasis&#44; the first step in all patients should be to substitute the drug by another with a rapid response&#44; such as ciclosporin or ustekinumab&#44; to treat the episode&#46;</p></li><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">&#8226;</span><p id="par0300" class="elsevierStylePara elsevierViewall">In patients with a change in the morphology of the psoriasis&#44; which is not serious in the majority of cases&#44; the most widely used initial option is to continue using the same drug at the same dose and to prescribe topical therapy&#46; If this is insufficient to control the episode&#44; we recommend substitution of the first agent by another drug&#44; preferably one with a different mechanism of action&#44; as in cases of new onset psoriasis<span class="elsevierStyleItalic">&#46;</span> Though possible&#44; the option to add another systemic drug is&#44; in our experience&#44; less effective&#46; This delays the substitution&#44; which will be necessary in the large majority of patients in the end&#46; However&#44; therapeutic modalities such as phototherapy in monotherapy or in combination with acitretin in mild or moderate cases&#44; or drugs such as ciclosporin or methotrexate in more serious cases&#44; have been shown to be useful in some patients&#44; as mentioned above in the text&#46;</p></li></ul></p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Ethical Disclosures</span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Protection of human and animal subjects</span><p id="par0305" class="elsevierStylePara elsevierViewall">The authors declare that no experiments were performed on humans or animals for this investigation&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Confidentiality of data</span><p id="par0310" class="elsevierStylePara elsevierViewall">The authors declare that they followed their hospital&#39;s regulations regarding the publication of patient information and that written informed consent for voluntary participation was obtained for all patients&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Right to privacy and informed consent</span><p id="par0315" class="elsevierStylePara elsevierViewall">The authors declare that no private patient data are disclosed in this article&#46;</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Conflicts of Interest</span><p id="par0320" class="elsevierStylePara elsevierViewall">Dr E&#46; Daud&#233;n undertakes or has undertaken the following activities&#58; member of Advisory Boards&#44; consultant&#44; reception of grants&#44; research support&#44; participation in clinical trials and fees for lectures with the following pharmaceutical companies&#58; Abbott&#44; Astellas&#44; Biogen&#44; Centocor Ortho Biotech Inc&#44; Galderma&#44; Glaxo&#44; Janssen-Cilag&#44; Leo Pharma&#44; MSD&#44; Pfizer&#44; Novartis&#44; Stiefel&#44; Wyeth Pharmaceuticals&#44; 3<span class="elsevierStyleHsp" style=""></span>M and Celgene&#46;</p><p id="par0325" class="elsevierStylePara elsevierViewall">Dr&#46; R&#46; Navarro declares that she has no conflicts of interest&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:2 [
          "identificador" => "xres372204"
          "titulo" => "Abstract"
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec351325"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "xres372203"
          "titulo" => "Resumen"
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec351324"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Classification"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Pathogenesis of Psoriasiform Reactions"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "New Onset Psoriasis"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Exacerbation of Previous Psoriasis"
            ]
            2 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Exacerbation of Previous Psoriasis With No Change in Morphology"
            ]
            3 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Exacerbation of Previous Psoriasis With a Change in Morphology"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Histopathologic Characteristics"
        ]
        8 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Initial Management"
        ]
        9 => array:3 [
          "identificador" => "sec0050"
          "titulo" => "Ethical Disclosures"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "Protection of human and animal subjects"
            ]
            1 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Confidentiality of data"
            ]
            2 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Right to privacy and informed consent"
            ]
          ]
        ]
        10 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Conflicts of Interest"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2012-12-31"
    "fechaAceptado" => "2013-05-25"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec351325"
          "palabras" => array:8 [
            0 => "Psoriasis"
            1 => "Palmoplantar pustulosis"
            2 => "Guttate psoriasis"
            3 => "Erythrodermia"
            4 => "Tumor necrosis factor"
            5 => "Psoriasiform reactions"
            6 => "Adverse effects"
            7 => "Induced psoriasis"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec351324"
          "palabras" => array:8 [
            0 => "Psoriasis"
            1 => "Pustulosis palmoplantar"
            2 => "Psoriasis guttata"
            3 => "Eritrodermia"
            4 => "Factor de necrosis tumoral"
            5 => "Reacciones psoriasiformes"
            6 => "Efectos adversos"
            7 => "Psoriasis inducida"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">There have been reports of paradoxical induction or worsening of psoriasis during treatment with tumor necrosis factor &#40;TNF&#41; &#945; agents &#40;infliximab&#44; etanercept&#44; adalimumab&#44; and certolizumab&#41;&#46; It has been hypothesized that an imbalance between TNF-&#945; and interferon &#945; might have a role in the etiology and pathogenesis of these reactions&#46; Paradoxical psoriasiform reactions can be divided clinically into de novo psoriasis and exacerbation of preexisting psoriasis&#46; The first&#44; which is more common and more extensively described in the literature&#44; occurs in patients without a history of psoriasis who are receiving TNF-&#945; therapy for another inflammatory disorder&#46; The second can occur with or without changes in the morphology of the lesions&#46; In this article&#44; we review the literature on the clinical and histologic features of paradoxical psoriasiform reactions&#44; analyze their clinical course and treatment&#44; and propose a clinical management model for use in routine practice&#46;</p>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Parad&#243;jicamente se han descrito casos de inducci&#243;n o empeoramiento de una psoriasis durante el tratamiento con todos los agentes anti-factor de necrosis tumoral &#945; &#40;anti-TNF&#945;&#41; &#40;infliximab&#44; etanercept&#44; adalimumab y certolizumab&#41;&#46; Se ha postulado que la alteraci&#243;n del equilibrio entre el TNF&#945; y el interfer&#243;n &#945; estar&#237;a implicada en su etiopatogenia&#46; Cl&#237;nicamente se distinguen varios patrones de reacciones psoriasiformes parad&#243;jicas&#58; la psoriasis <span class="elsevierStyleItalic">de novo</span> en pacientes que no han presentado anteriormente esta enfermedad y que reciben este tratamiento por otra enfermedad inflamatoria&#44; que es la m&#225;s frecuente y la mejor descrita&#44; y la exacerbaci&#243;n de una psoriasis preexistente durante la terapia anti-TNF&#945;&#44; que puede presentarse con o sin un cambio de morfolog&#237;a&#46; En este trabajo realizamos una revisi&#243;n de la literatura en relaci&#243;n con las caracter&#237;sticas cl&#237;nicas e histol&#243;gicas de este tipo de reacciones&#44; as&#237; como de su evoluci&#243;n y tratamiento&#44; y planteamos un esquema de manejo en la pr&#225;ctica cl&#237;nica&#46;</p>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Navarro R&#44; Daud&#233;n E&#46; Reacciones psoriasiformes parad&#243;jicas durante el tratamiento con terapia anti-factor de necrosis tumoral&#46; Manejo cl&#237;nico&#46; Actas Dermosifiliogr&#46; 2014&#59;105&#58;752&#8211;761&#46;</p>"
      ]
    ]
    "multimedia" => array:8 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 773
            "Ancho" => 1559
            "Tamanyo" => 88031
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Classification of paradoxical psoriasiform reactions&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 751
            "Ancho" => 996
            "Tamanyo" => 122653
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Desquamating erythematous plaques with pustules on their surface&#46; These developed on the palms of a patient on treatment with adalimumab for rheumatoid arthritis&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 1610
            "Ancho" => 1001
            "Tamanyo" => 179656
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Patient with a history of plaque psoriasis who presented a sudden outbreak of small desquamating erythematous plaques with a drop-like appearance&#58; A&#44; On the abdomen&#46; B&#44; On the posterior aspect of the lower limbs&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Abbreviation&#58; TNF&#44; tumor necrosis factor&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Reference&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Type of Reaction&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Underlying Disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Total No&#46; of Patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">No&#46; of Patients Receiving Each Anti-TNF-&#945; Agent&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Kary et al&#46; &#40;2006&#41;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatoid arthritis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 2&#59; Etanercept&#44; 3&#59; Adalimumab&#44; 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exacerbation with no morphological changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 2&#59; Etanercept&#44; 3&#59; Adalimumab&#44; 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Goiriz et al&#46; &#40;2006&#41;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatologic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 1&#59; Adalimumab&#44; 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Morphological changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Etanercept&#44; 6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">De Gannes et al&#46; &#40;2007&#41;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatologic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 5&#59; Etanercept&#44; 6&#59; Adalimumab&#44; 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lee et al&#46; &#40;2007&#41;<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">69</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatologic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 3&#59; Etanercept&#44; 2&#59; Adalimumab&#44; 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Exacerbation with no morphological changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Etanercept&#44; 1&#59; Adalimumab&#44; 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Seneschal et al&#46; &#40;2007&#41;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatologic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 7&#59; Etanercept&#44; 3&#59; Adalimumab&#44; 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Harrison et al&#46; &#40;2009&#41;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatoid arthritis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 6&#59; Etanercept&#44; 6&#59; Adalimumab&#44; 13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cullen et al&#46; &#40;2011&#41;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inflammatory bowel disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 21&#59; Adalimumab&#44; 7&#59; Certolizumab&#44; 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Guerra et al<span class="elsevierStyleItalic">&#46;</span> &#40;2012&#41;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inflammatory bowel disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 14&#59; Adalimumab&#44; 7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab562533.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Review of the Literature&#58; Articles With at Least 8 Patients who Developed Paradoxical Psoriasiform Reactions During Treatment With Tumor Necrosis Factor &#945; Inhibitors&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Abbreviation&#58; TNF&#44; tumor necrosis factor&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Reference&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Type of Reaction&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Underlying Disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Total No&#46; of Patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Percentage of Cases With the Different Anti-TNF-&#945; Agents&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Collamer et al&#46; &#40;2008&#41;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset psoriasis and exacerbations with&#47;without morphological changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatologic&#44; gastrointestinal&#44; and psoriatic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">104&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 53&#59; Etanercept&#44; 29&#59; Adalimumab&#44; 18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Wollina et al&#46; &#40;2008&#41;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset psoriasis and exacerbations with&#47;without morphological changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatologic&#44; gastrointestinal&#44; and psoriatic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">120&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 52&#46;5&#59; Etanercept&#44; 30&#46;8&#59; Adalimumab&#44; 21&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ko et al&#46; &#40;2009&#41;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset psoriasis and exacerbations with&#47;without morphological changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatologic&#44; gastrointestinal&#44; and psoriatic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">127&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 55&#46;1&#59; Etanercept&#44; 27&#46;6&#59; Adalimumab&#44; 17&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Collamer et al&#46; &#40;2010&#41;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset psoriasis and exacerbations with&#47;without morphological changes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rheumatologic&#44; gastrointestinal&#44; and psoriatic&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">207&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 59&#59; Etanercept&#44; 19&#59; Adalimumab&#44; 22&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cullen et al&#46; &#40;2011&#41;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gastrointestinal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">120&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 79&#59; Adalimumab&#44; 17&#59; Certolizumab&#44; 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Denadai et al&#46; &#40;2012&#41;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New onset psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gastrointestinal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">222&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximab&#44; 69&#46;4&#59; Adalimumab&#44; 22&#46;5&#59; Certolizumab&#44; 2&#46;7&#59;Not specified&#44; 5&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab562537.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Most Relevant Revisions Published in the Literature&#46;</p>"
        ]
      ]
      5 => array:7 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Medical Background&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">History of the Underlying Disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Additional Tests&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Medical and surgical diseasesUsual medication&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Clinical coursePrevious treatments&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disease durationClinical formsPersonal&#47;family backgroundExclude triggers&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Routine blood testsSkin biopsy for confirmation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab562536.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Initial Management of Patients With New Onset Psoriasis During Treatment With Tumor Necrosis Factor &#945; Inhibitors&#46;</p>"
        ]
      ]
      6 => array:7 [
        "identificador" => "tbl0020"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Abbreviations&#58; ASLO&#44; antistreptolysin O antibody&#59; TNF&#44; tumor necrosis factor&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Medical Background&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Previous Form of Psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Episode of Psoriasis During anti-TNF-&#945; Treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Additional Tests&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Medical and surgical diseasesUsual medication&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Clinical courseClinical formsPrevious treatments&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disease durationClinical formsExclude triggers&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Routine blood tests&#44; ASLO&#44; and pharyngeal exudateSkin biopsy for confirmation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab562534.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Initial Management of Patients With an Exacerbation of Previously Diagnosed Psoriasis During Treatment With Tumor Necrosis Factor &#945; Inhibitors&#46;</p>"
        ]
      ]
      7 => array:7 [
        "identificador" => "tbl0025"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" style="border-bottom: 2px solid black">Treatment Sequence&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46; Add topical therapy &#40;high-strength corticosteroids&#44; vitamin D analogs&#44; or combinations of the two&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46; Substitute the implicated drug &#40;preferably by one with a different mechanism of action&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46; Combined therapy with another systemic treatment&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>In mild or moderate cases&#58; phototherapy and&#47;or acitretin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>In severe cases&#58; ciclosporin or methotrexate<span class="elsevierStyleHsp" style=""></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab562535.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">General Treatment of Paradoxical Psoriasiform Reactions&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:73 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "F&#46;O&#46; Nestle"
                            1 => "D&#46;H&#46; Kaplan"
                            2 => "J&#46; Barker"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMra0804595"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2009"
                        "volumen" => "361"
                        "paginaInicial" => "496"
                        "paginaFinal" => "509"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19641206"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Triggering psoriasis&#58; The role of infections and medications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "L&#46; Fry"
                            1 => "B&#46;S&#46; Baker"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.clindermatol.2007.08.015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Dermatol"
                        "fecha" => "2007"
                        "volumen" => "25"
                        "paginaInicial" => "606"
                        "paginaFinal" => "615"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18021899"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Integrated approach to comorbidity in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "Working Group on Psoriasis-associated comorbidities"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Dauden"
                            1 => "S&#46; Castaneda"
                            2 => "C&#46; Suarez"
                            3 => "J&#46; Garcia-Campayo"
                            4 => "A&#46;J&#46; Blasco"
                            5 => "M&#46;D&#46; Aguilar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0001-7310(12)70001-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2012"
                        "volumen" => "103"
                        "paginaInicial" => "1"
                        "paginaFinal" => "64"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22364603"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Dauden"
                            1 => "S&#46; Castaneda"
                            2 => "C&#46; Suarez"
                            3 => "J&#46; Garcia-Campayo"
                            4 => "A&#46;J&#46; Blasco"
                            5 => "M&#46;D&#46; Aguilar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2012"
                        "volumen" => "103"
                        "paginaInicial" => "1"
                        "paginaFinal" => "64"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Putting together the psoriasis puzzle&#58; An update on developing targeted therapies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "L&#46;M&#46; Johnson-Huang"
                            1 => "M&#46;A&#46; Lowes"
                            2 => "J&#46;G&#46; Krueger"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1242/dmm.009092"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dis Model Mech"
                        "fecha" => "2012"
                        "volumen" => "5"
                        "paginaInicial" => "423"
                        "paginaFinal" => "433"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22730473"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis&#58; Meta and exposure-adjusted pooled analyses of serious adverse events"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;P&#46; Leombruno"
                            1 => "T&#46;R&#46; Einarson"
                            2 => "E&#46;C&#46; Keystone"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2008.091025"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2009"
                        "volumen" => "68"
                        "paginaInicial" => "1136"
                        "paginaFinal" => "1145"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18753157"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Etanercept and infections"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46; Ribera"
                            1 => "L&#46; Leal"
                            2 => "J&#46; Luelmo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2010"
                        "volumen" => "101"
                        "paginaInicial" => "70"
                        "paginaFinal" => "76"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20492884"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adverse effects of biological agents in the treatment of psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "F&#46; Rongioletti"
                            1 => "M&#46; Burlando"
                            2 => "A&#46; Parodi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2165/1153420-S0-000000000-00000"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol"
                        "fecha" => "2010"
                        "volumen" => "11"
                        "paginaInicial" => "35"
                        "paginaFinal" => "37"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20586505"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata&#58; First 120 cases from the literature including a series of six new patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "U&#46; Wollina"
                            1 => "G&#46; Hansel"
                            2 => "A&#46; Koch"
                            3 => "J&#46; Schonlebe"
                            4 => "E&#46; Kostler"
                            5 => "G&#46; Haroske"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol"
                        "fecha" => "2008"
                        "volumen" => "9"
                        "paginaInicial" => "1"
                        "paginaFinal" => "14"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18092839"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous side effects of anti-tumor necrosis factor biologic therapy&#58; A clinical review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "A&#46;E&#46; Moustou"
                            1 => "A&#46; Matekovits"
                            2 => "C&#46; Dessinioti"
                            3 => "C&#46; Antoniou"
                            4 => "P&#46;P&#46; Sfikakis"
                            5 => "A&#46;J&#46; Stratigos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2008.10.060"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2009"
                        "volumen" => "61"
                        "paginaInicial" => "486"
                        "paginaFinal" => "504"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19628303"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Integrated safety analysis&#58; Short- and long-term safety profiles of etanercept in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;M&#46; Pariser"
                            1 => "C&#46;L&#46; Leonardi"
                            2 => "K&#46; Gordon"
                            3 => "A&#46;B&#46; Gottlieb"
                            4 => "S&#46; Tyring"
                            5 => "K&#46;A&#46; Papp"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2011.07.040"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2012"
                        "volumen" => "67"
                        "paginaInicial" => "245"
                        "paginaFinal" => "256"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22015149"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adalimumab therapy for moderate to severe psoriasis&#58; A randomized&#44; controlled phase <span class="elsevierStyleSmallCaps">iii</span>trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Menter"
                            1 => "S&#46;K&#46; Tyring"
                            2 => "K&#46; Gordon"
                            3 => "A&#46;B&#46; Kimball"
                            4 => "C&#46;L&#46; Leonardi"
                            5 => "R&#46;G&#46; Langley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2007.09.010"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2008"
                        "volumen" => "58"
                        "paginaInicial" => "106"
                        "paginaFinal" => "115"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17936411"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical response to adalimumab treatment in patients with moderate to severe psoriasis&#58; Double-blind&#44; randomized controlled trial and open-label extension study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;B&#46; Gordon"
                            1 => "R&#46;G&#46; Langley"
                            2 => "C&#46; Leonardi"
                            3 => "D&#46; Toth"
                            4 => "M&#46;A&#46; Menter"
                            5 => "S&#46; Kang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2006.05.027"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2006"
                        "volumen" => "55"
                        "paginaInicial" => "598"
                        "paginaFinal" => "606"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17010738"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;B&#46; Gordon"
                            1 => "A&#46;B&#46; Gottlieb"
                            2 => "C&#46;L&#46; Leonardi"
                            3 => "B&#46;E&#46; Elewski"
                            4 => "A&#46; Wang"
                            5 => "A&#46; Jahreis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546630500472838"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat"
                        "fecha" => "2006"
                        "volumen" => "17"
                        "paginaInicial" => "9"
                        "paginaFinal" => "17"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16467018"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of infliximab vs methotrexate in patients with moderate-to-severe plaque psoriasis&#58; Results of an open-label&#44; active-controlled&#44; randomized trial &#40;RESTORE1&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Barker"
                            1 => "M&#46; Hoffmann"
                            2 => "G&#46; Wozel"
                            3 => "J&#46;P&#46; Ortonne"
                            4 => "H&#46; Zheng"
                            5 => "H&#46; van Hoogstraten"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2011.10615.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2011"
                        "volumen" => "165"
                        "paginaInicial" => "1109"
                        "paginaFinal" => "1117"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21910713"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of biologics in the treatment of moderate to severe psoriasis&#58; A network meta-analysis of randomized controlled trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "K&#46; Reich"
                            1 => "A&#46;D&#46; Burden"
                            2 => "J&#46;N&#46; Eaton"
                            3 => "N&#46;S&#46; Hawkins"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2011.10583.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2012"
                        "volumen" => "166"
                        "paginaInicial" => "179"
                        "paginaFinal" => "188"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21910698"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infliximab induction and maintenance therapy for moderate-to-severe psoriasis&#58; A phase <span class="elsevierStyleSmallCaps">iii</span>&#44; multicentre&#44; double-blind trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Reich"
                            1 => "F&#46;O&#46; Nestle"
                            2 => "K&#46; Papp"
                            3 => "J&#46;P&#46; Ortonne"
                            4 => "R&#46; Evans"
                            5 => "C&#46; Guzzo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(05)67566-6"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2005"
                        "volumen" => "366"
                        "paginaInicial" => "1367"
                        "paginaFinal" => "1374"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16226614"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tumor necrosis factor-a antagonist-induced psoriasis&#58; Yet another paradox in medicine"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Aslanidis"
                            1 => "A&#46; Pyrpasopoulou"
                            2 => "S&#46; Douma"
                            3 => "A&#46; Triantafyllou"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10067-007-0789-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Rheumatol"
                        "fecha" => "2008"
                        "volumen" => "27"
                        "paginaInicial" => "377"
                        "paginaFinal" => "380"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17994192"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Paradoxical worsening of psoriasis when switching from etanercept to adalimumab&#58; A case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "T&#46; Bhutani"
                            1 => "J&#46; Koo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3109/09546630903559814"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat"
                        "fecha" => "2011"
                        "volumen" => "22"
                        "paginaInicial" => "75"
                        "paginaFinal" => "78"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20524874"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Boms"
                            1 => "T&#46; Sehr"
                            2 => "U&#46; Jappe"
                            3 => "A&#46; Enk"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00105-007-1451-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hautarzt"
                        "fecha" => "2008"
                        "volumen" => "59"
                        "paginaInicial" => "653"
                        "paginaFinal" => "655"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18210001"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diffused suberitrodermic psoriasis induced by infliximab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "V&#46; Bruzzese"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Reumatismo"
                        "fecha" => "2007"
                        "volumen" => "59"
                        "paginaInicial" => "328"
                        "paginaFinal" => "331"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18157290"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "V&#46; Bruzzese"
                            1 => "J&#46; Pepe"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Immunopathol Pharmacol"
                        "fecha" => "2009"
                        "volumen" => "22"
                        "paginaInicial" => "235"
                        "paginaFinal" => "238"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19309571"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Cavailhes"
                            1 => "S&#46; Ingen-Housz-Oro"
                            2 => "S&#46; Djennane"
                            3 => "M&#46; Rafaa"
                            4 => "F&#46; Fiszenson-Albala"
                            5 => "N&#46; Weber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Dermatol Venereol"
                        "fecha" => "2007"
                        "volumen" => "134"
                        "paginaInicial" => "363"
                        "paginaFinal" => "367"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17483757"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New-onset psoriasis associated with etanercept therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "L&#46;A&#46; Chen"
                            1 => "L&#46;H&#46; Su"
                            2 => "Y&#46;J&#46; Chang"
                            3 => "Y&#46;L&#46; Hsu"
                            4 => "T&#46;H&#46; Tsai"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1346-8138.2010.00789.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatol"
                        "fecha" => "2010"
                        "volumen" => "37"
                        "paginaInicial" => "378"
                        "paginaFinal" => "380"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20507411"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy&#58; Clinical features and possible immunopathogenesis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;N&#46; Collamer"
                            1 => "D&#46;F&#46; Battafarano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semarthrit.2010.04.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Arthritis Rheum"
                        "fecha" => "2010"
                        "volumen" => "40"
                        "paginaInicial" => "233"
                        "paginaFinal" => "240"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20580412"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy&#58; A literature review and potential mechanisms of action"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46;N&#46; Collamer"
                            1 => "K&#46;T&#46; Guerrero"
                            2 => "J&#46;S&#46; Henning"
                            3 => "D&#46;F&#46; Battafarano"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.23835"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2008"
                        "volumen" => "59"
                        "paginaInicial" => "996"
                        "paginaFinal" => "1001"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18576309"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease&#58; A new series and a review of 120 cases from the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "G&#46; Cullen"
                            1 => "D&#46; Kroshinsky"
                            2 => "A&#46;S&#46; Cheifetz"
                            3 => "J&#46;R&#46; Korzenik"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2036.2011.04866.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther"
                        "fecha" => "2011"
                        "volumen" => "34"
                        "paginaInicial" => "1318"
                        "paginaFinal" => "1327"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21957906"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease&#58; A systematic literature review based on 222 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Denadai"
                            1 => "F&#46;V&#46; Teixeira"
                            2 => "F&#46; Steinwurz"
                            3 => "R&#46; Romiti"
                            4 => "R&#46; Saad-Hossne"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.crohns.2012.08.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Crohns Colitis"
                        "fecha" => "2013"
                        "volumen" => "7"
                        "paginaInicial" => "517"
                        "paginaFinal" => "524"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22960136"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis induced by infliximab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "I&#46;C&#46; Fernandes"
                            1 => "T&#46; Torres"
                            2 => "M&#46; Sanches"
                            3 => "G&#46; Velho"
                            4 => "P&#46; Lago"
                            5 => "M&#46; Selores"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Med Port"
                        "fecha" => "2011"
                        "volumen" => "24"
                        "paginaInicial" => "709"
                        "paginaFinal" => "712"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22856418"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies&#58; A retrospective study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46; Fouache"
                            1 => "V&#46; Goeb"
                            2 => "N&#46; Massy-Guillemant"
                            3 => "G&#46; Avenel"
                            4 => "H&#46; Bacquet-Deschryver"
                            5 => "M&#46; Kozyreff-Meurice"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;"
                        "fecha" => "2009"
                        "volumen" => "48"
                        "paginaInicial" => "761"
                        "paginaFinal" => "764"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Goiriz"
                            1 => "E&#46; Dauden"
                            2 => "S&#46; Perez-Gala"
                            3 => "G&#46; Guhl"
                            4 => "A&#46; Garcia-Diez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2230.2006.02315.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol"
                        "fecha" => "2007"
                        "volumen" => "32"
                        "paginaInicial" => "176"
                        "paginaFinal" => "179"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17176269"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy&#58; A review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "B&#46; Grinblat"
                            1 => "M&#46; Scheinberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semarthrit.2007.05.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Arthritis Rheum"
                        "fecha" => "2008"
                        "volumen" => "37"
                        "paginaInicial" => "251"
                        "paginaFinal" => "255"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17640718"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease&#58; A report of 21 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46; Guerra"
                            1 => "A&#46; Algaba"
                            2 => "J&#46;L&#46; Perez-Calle"
                            3 => "M&#46; Chaparro"
                            4 => "I&#46; Marin-Jimenez"
                            5 => "R&#46; Garcia-Castellanos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.crohns.2011.10.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Crohns Colitis"
                        "fecha" => "2012"
                        "volumen" => "6"
                        "paginaInicial" => "518"
                        "paginaFinal" => "523"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22398059"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infliximab and adalimumab-induced psoriasis in Crohn&#39;s disease&#58; A paradoxical side effect"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46; Iborra"
                            1 => "B&#46; Beltran"
                            2 => "G&#46; Bastida"
                            3 => "M&#46; Aguas"
                            4 => "P&#46; Nos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.crohns.2010.11.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Crohns Colitis"
                        "fecha" => "2011"
                        "volumen" => "5"
                        "paginaInicial" => "157"
                        "paginaFinal" => "161"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21453886"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis&#58; Is it really a paradoxical side effect&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "C&#46; Joyau"
                            1 => "G&#46; Veyrac"
                            2 => "V&#46; Dixneuf"
                            3 => "P&#46; Jolliet"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Rheumatol"
                        "fecha" => "2012"
                        "volumen" => "30"
                        "paginaInicial" => "700"
                        "paginaFinal" => "706"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22935567"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Kary"
                            1 => "M&#46; Worm"
                            2 => "H&#46; Audring"
                            3 => "D&#46; Huscher"
                            4 => "M&#46; Renelt"
                            5 => "H&#46; Sorensen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2005.037424"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2006"
                        "volumen" => "65"
                        "paginaInicial" => "405"
                        "paginaFinal" => "407"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16150791"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Induction and exacerbation of psoriasis with TNF-blockade therapy&#58; A review and analysis of 127 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;M&#46; Ko"
                            1 => "A&#46;B&#46; Gottlieb"
                            2 => "J&#46;F&#46; Kerbleski"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546630802441234"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat"
                        "fecha" => "2009"
                        "volumen" => "20"
                        "paginaInicial" => "100"
                        "paginaFinal" => "108"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18923992"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis induced by infliximab in a patient suffering from Crohn&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "E&#46; Manni"
                            1 => "P&#46; Barachini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Immunopathol Pharmacol"
                        "fecha" => "2009"
                        "volumen" => "22"
                        "paginaInicial" => "841"
                        "paginaFinal" => "844"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19822070"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis&#58; Report on five cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46; Mossner"
                            1 => "D&#46; Thaci"
                            2 => "J&#46; Mohr"
                            3 => "S&#46; Patzold"
                            4 => "H&#46;P&#46; Bertsch"
                            5 => "U&#46; Kruger"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00403-008-0831-8"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol Res"
                        "fecha" => "2008"
                        "volumen" => "300"
                        "paginaInicial" => "101"
                        "paginaFinal" => "105"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18239925"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "B&#46;C&#46; Park"
                            1 => "H&#46;J&#46; Lim"
                            2 => "B&#46;S&#46; Kim"
                            3 => "W&#46;J&#46; Lee"
                            4 => "W&#46; Kim Do"
                            5 => "S&#46;J&#46; Lee"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.5021/ad.2009.21.1.60"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Dermatol"
                        "fecha" => "2009"
                        "volumen" => "21"
                        "paginaInicial" => "60"
                        "paginaFinal" => "62"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20548859"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous manifestations in inflammatory bowel diseases&#58; eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Passarini"
                            1 => "S&#46;D&#46; Infusino"
                            2 => "E&#46; Barbieri"
                            3 => "E&#46; Varotti"
                            4 => "P&#46; Gionchetti"
                            5 => "F&#46; Rizzello"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000107622"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatology"
                        "fecha" => "2007"
                        "volumen" => "215"
                        "paginaInicial" => "295"
                        "paginaFinal" => "300"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17911986"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biologics-induced autoimmune diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "R&#46; Perez-Alvarez"
                            1 => "M&#46; Perez-de-Lis"
                            2 => "M&#46; Ramos-Casals"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Curr Opin Rheumatol"
                        "fecha" => "2012"
                        "itemHostRev" => array:3 [
                          "pii" => "S1063458413009400"
                          "estado" => "S300"
                          "issn" => "10634584"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis&#58; Case report and review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46; Puig"
                             …3
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000339864"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatology"
                        "fecha" => "2012"
                        "volumen" => "225"
                        "paginaInicial" => "14"
                        "paginaFinal" => "17"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis&#58; A &#171;class effect&#187; of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3109/09546630902882089"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat"
                        "fecha" => "2010"
                        "volumen" => "21"
                        "paginaInicial" => "3"
                        "paginaFinal" => "5"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A case of infliximab-induced psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Online J"
                        "fecha" => "2008"
                        "volumen" => "14"
                        "paginaInicial" => "9"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/RHU.0b013e31823262c3"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Rheumatol"
                        "fecha" => "2011"
                        "volumen" => "17"
                        "paginaInicial" => "385"
                        "paginaFinal" => "386"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ustekinumab in a patient with Crohn&#39;s disease and anti-TNF-alpha-induced psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.gastrohep.2011.04.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterol Hepatol"
                        "fecha" => "2011"
                        "volumen" => "34"
                        "paginaInicial" => "546"
                        "paginaFinal" => "550"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2009.09329.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2009"
                        "volumen" => "161"
                        "paginaInicial" => "1081"
                        "paginaFinal" => "1088"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis induced by anti-tumor necrosis factor therapy&#58; A paradoxical adverse reaction"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.21233"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2005"
                        "volumen" => "52"
                        "paginaInicial" => "2513"
                        "paginaFinal" => "2518"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infliximab-induced psoriasis during therapy for Crohn&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.crohns.2011.12.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Crohns Colitis"
                        "fecha" => "2012"
                        "volumen" => "6"
                        "paginaInicial" => "610"
                        "paginaFinal" => "616"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Paradoxical adverse effects of anti-TNF-alpha treatment&#58; Onset or exacerbation of cutaneous disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1586/eci.09.18"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Clin Immunol"
                        "fecha" => "2009"
                        "volumen" => "5"
                        "paginaInicial" => "421"
                        "paginaFinal" => "431"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis and pustular dermatitis triggered by TNF-&#123;alpha&#125; inhibitors in patients with rheumatologic conditions"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archderm.143.2.223"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Dermatol"
                        "fecha" => "2007"
                        "volumen" => "143"
                        "paginaInicial" => "223"
                        "paginaFinal" => "231"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biologic therapy &#40;TNF-alpha antagonists&#41;-induced psoriasis&#58; A cytokine imbalance between TNF-alpha and IFN-alpha&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/RHU.0b013e318190dd88"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Rheumatol"
                        "fecha" => "2008"
                        "volumen" => "14"
                        "paginaInicial" => "353"
                        "paginaFinal" => "356"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy&#58; Results from the British Society for Rheumatology Biologics Register"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2007.087288"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2009"
                        "volumen" => "68"
                        "paginaInicial" => "209"
                        "paginaFinal" => "215"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy&#58; Description of 3 cases and review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Rheumatol"
                        "fecha" => "2010"
                        "volumen" => "28"
                        "paginaInicial" => "408"
                        "paginaFinal" => "410"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasiform skin reactions during treatment with etanercept"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2010"
                        "volumen" => "101"
                        "paginaInicial" => "106"
                        "paginaFinal" => "110"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2010.09669.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2010"
                        "volumen" => "162"
                        "paginaInicial" => "1144"
                        "paginaFinal" => "1146"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Review article&#58; Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2036.2009.03955.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther"
                        "fecha" => "2009"
                        "volumen" => "29"
                        "paginaInicial" => "921"
                        "paginaFinal" => "927"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anti-tumor necrosis factor-alpha-induced psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "2006"
                        "volumen" => "33"
                        "paginaInicial" => "1411"
                        "paginaFinal" => "1414"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S1888441513000647"
                          "estado" => "S300"
                          "issn" => "18884415"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Occurrence of plantar pustular psoriasis during treatment with infliximab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Cutan Med Surg"
                        "fecha" => "2009"
                        "volumen" => "13"
                        "paginaInicial" => "40"
                        "paginaFinal" => "42"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jbspin.2007.06.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Joint Bone Spine"
                        "fecha" => "2008"
                        "volumen" => "75"
                        "paginaInicial" => "315"
                        "paginaFinal" => "318"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anti-tumor necrosis factor alpha-induced psoriasiform eruptions&#58; Three further cases and current overview"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000095033"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatology"
                        "fecha" => "2006"
                        "volumen" => "213"
                        "paginaInicial" => "182"
                        "paginaFinal" => "186"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0315"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous manifestations during treatment with TNF-alpha blockers&#58; 11 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Dermatol Venereol"
                        "fecha" => "2007"
                        "volumen" => "134"
                        "paginaInicial" => "337"
                        "paginaFinal" => "342"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0320"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous adverse reaction to infliximab&#58; Report of psoriasis developing in 3 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cutis"
                        "fecha" => "2007"
                        "volumen" => "80"
                        "paginaInicial" => "231"
                        "paginaFinal" => "237"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0325"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guttate psoriasis induced by infliximab in a child with Crohn&#39;s disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/ibd.20450"
                      "Revista" => array:6 [
                        "tituloSerie" => "Inflamm Bowel Dis"
                        "fecha" => "2008"
                        "volumen" => "14"
                        "paginaInicial" => "1462"
                        "paginaFinal" => "1463"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0330"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Cutan Med Surg"
                        "fecha" => "2011"
                        "volumen" => "15"
                        "paginaInicial" => "280"
                        "paginaFinal" => "284"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0335"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Infliximab can precipitate as well as worsen palmoplantar pustulosis&#58; Possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2005.06977.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2005"
                        "volumen" => "153"
                        "paginaInicial" => "1243"
                        "paginaFinal" => "1244"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0340"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy&#46; A study of 16 biopsies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/DAD.0b013e3181cb3ff7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Dermatopathol"
                        "fecha" => "2010"
                        "volumen" => "32"
                        "paginaInicial" => "568"
                        "paginaFinal" => "573"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0345"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2007.07682.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2007"
                        "volumen" => "156"
                        "paginaInicial" => "486"
                        "paginaFinal" => "491"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0350"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Letter&#58; A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Online J"
                        "fecha" => "2011"
                        "volumen" => "17"
                        "paginaInicial" => "11"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Letter&#58; Pathogenesis of tumour necrosis factor-alpha antagonists-induced psoriasiform lesions"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2036.2012.05126.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther"
                        "fecha" => "2012"
                        "volumen" => "36"
                        "paginaInicial" => "77"
                        "paginaFinal" => "78"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab&#58; Should biological therapy be suspended&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arq Gastroenterol"
                        "fecha" => "2012"
                        "volumen" => "49"
                        "paginaInicial" => "172"
                        "paginaFinal" => "176"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Episode of pustular psoriasis after a tuberculin test in a patient with plaque psoriasis on treatment with etanercept"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2011.04.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2011"
                        "volumen" => "102"
                        "paginaInicial" => "828"
                        "paginaFinal" => "830"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/15782190/0000010500000008/v1_201409260034/S1578219014002133/v1_201409260034/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6151"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Practical Dermatology"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010500000008/v1_201409260034/S1578219014002133/v1_201409260034/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219014002133?idApp=UINPBA000044"
]

Article information

ISSN: 15782190
Original language: English

DOI:10.1016/j.adengl.2013.05.011

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	11	6	17
2024 October	197	56	253
2024 September	197	46	243
2024 August	249	83	332
2024 July	215	68	283
2024 June	176	54	230
2024 May	185	63	248
2024 April	177	41	218
2024 March	188	49	237
2024 February	150	51	201
2024 January	132	51	183
2023 December	174	43	217
2023 November	196	52	248
2023 October	154	50	204
2023 September	182	52	234
2023 August	123	41	164
2023 July	176	73	249
2023 June	147	73	220
2023 May	183	95	278
2023 April	122	111	233
2023 March	105	83	188
2023 February	89	75	164
2023 January	89	83	172
2022 December	66	77	143
2022 November	32	105	137
2022 October	49	81	130
2022 September	28	126	154
2022 August	51	84	135
2022 July	30	90	120
2022 June	37	97	134
2022 May	83	130	213
2022 April	97	109	206
2022 March	72	119	191
2022 February	94	118	212
2022 January	85	108	193
2021 December	71	89	160
2021 November	64	100	164
2021 October	84	105	189
2021 September	56	92	148
2021 August	92	86	178
2021 July	96	153	249
2021 June	60	67	127
2021 May	48	60	108
2021 April	67	121	188
2021 March	127	70	197
2021 February	62	73	135
2021 January	46	33	79
2020 December	60	46	106
2020 November	39	52	91
2020 October	39	28	67
2020 September	43	26	69
2020 August	50	70	120
2020 July	48	34	82
2020 June	32	43	75
2020 May	43	38	81
2020 April	37	32	69
2020 March	32	40	72
2020 February	3	29	32
2020 January	7	23	30
2019 December	8	29	37
2019 November	4	30	34
2019 October	0	24	24
2019 September	0	21	21
2019 August	8	18	26
2019 July	8	19	27
2019 June	4	26	30
2019 May	10	32	42
2019 April	14	66	80
2019 March	3	17	20
2019 February	5	15	20
2019 January	4	8	12
2018 December	1	9	10
2018 November	9	0	9
2018 October	8	0	8
2018 September	5	9	14
2018 August	0	30	30
2018 July	0	15	15
2018 June	0	12	12
2018 May	0	35	35
2018 April	0	12	12
2018 March	1	17	18
2018 February	38	20	58
2018 January	62	25	87
2017 December	64	26	90
2017 November	60	21	81
2017 October	50	27	77
2017 September	42	30	72
2017 August	67	55	122
2017 July	50	31	81
2017 June	98	50	148
2017 May	75	54	129
2017 April	49	33	82
2017 March	39	47	86
2017 February	37	39	76
2017 January	21	19	40
2016 December	38	28	66
2016 November	56	40	96
2016 October	33	52	85
2016 September	2	24	26
2016 August	0	13	13
2016 July	10	1	11
2016 June	9	8	17
2016 May	5	8	13
2016 April	9	4	13
2016 March	10	5	15
2016 February	10	8	18
2016 January	10	10	20
2015 December	18	2	20
2015 November	17	6	23
2015 October	10	13	23
2015 September	16	5	21
2015 August	14	6	20
2015 July	48	24	72
2015 June	35	13	48
2015 May	39	70	109
2015 April	24	23	47
2015 March	17	18	35
2015 February	13	3	16
2015 January	11	2	13
2014 December	9	11	20
2014 November	15	12	27
2014 October	22	10	32

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter